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Terminal erythroid maturation of mammalian erythroblasts is a unique 
differentiation system involving serial morphological changes accompanied by 
rapid cell cycling, followed by a precisely timed exit from the cell cycle and 
enucleation. The factors controlling erythroid differentiation such as 
erythropoietin signaling and the transcription factor GATA-1 have been 
widely studied. But the regulation of the late stage erythroid maturation 
changes such as the nuclear condensation, cell cycle arrest and enucleation are 
not well understood. We started this project with the aim of understanding the 
regulation of these critical events in mammalian terminal erythroid maturation 
using an in vitro primary erythroid cell culture system recently developed in 
our lab. We observed that Myc levels were rapidly downregulated during late 
stages of erythroid maturation coinciding with the exit from cell cycle and the 
onset of enucleation, suggesting that Myc may play a role in regulating one or 
both of these processes. The physiological relevance of these noticable 
changes in Myc expression during terminal erythroid maturation remained 
unclear due to conflicting reports in literature, prompting us to investigate the 
role of Myc in terminal erythropoiesis using our primary erythroid cell culture 
system. We used retrovirus-mediated overexpression and shRNA knockdown 
studies to elucidate the role of Myc in regulating terminal erythroid maturation. 
We observed that ectopic Myc expression had a dose-dependent effect on 
terminal erythroid differentiation of purified mouse fetal liver erythroblasts 
cultured in vitro. Ectopic Myc expression at physiological levels specifically 
blocked enucleation without affecting other aspects of terminal maturation, 
while overexpression of Myc at levels above the physiological range promoted 
 viii 
proliferation of the erythroblasts at the expense of differentiation as well as 
evoked an apoptotic response. Next, we demonstrated that the late stages of 
erythroblast maturation associated with nuclear condensation and enucleation 
was accompanied by global loss of acetylation at specific lysines of core 
histone N-terminal tails. Ectopic Myc expression inhibited nuclear 
condensation in late stage erythroid cells, and rescued the accompanying 
global histone deacetylation. The histone acetyltransferase (HAT) Gcn5 was 
upregulated by Myc, and ectopic Gcn5 expression caused a partial block in 
enucleation and inhibited net histone deacetylation and nuclear condensation 
in late stage erythroblasts. These observations, in light of recent reports on 
inhibition of nuclear condensation and enucleation by HDAC inhibitors, 
strongly suggest that histone deacetylation is necessary for erythroid nuclear 
condensation and enucleation. Finally, we used gene expression analysis using 
microarrays to compare and characterize the erythroid cells expressing Myc at 
physiological and supraphysiological levels. The transcriptome data showed 
that the G1-S cell cycle checkpoint and the erythropoietin signaling pathway 
were dysregulated upon Myc expression at supraphysiological levels in 
erythroblasts, leading to the continued proliferation at the expense of terminal 
differentiation in these cells. Taken together, we demonstrate that 
downregulation of Myc is essential for normal terminal erythroid 
differentiation and enucleation. Our data reveals an important role for Myc in 
erythroid nuclear condensation and enucleation, and provides further evidence 
for the emerging role of Myc in regulating global chromatin structure. 
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CHAPTER 1 – INTRODUCTION  
1.1. Mammalian terminal erythroid maturation  
In an adult human, the erythroid lineage has the largest output of new cell 
formation, with approximately 200 billion red blood cells produced everyday1. 
These red blood cells arise from the Hematopoietic Stem cells (HSC) through 
an exquisitely regulated multi-step process involving differentiation, 
commitment and proliferation. It involves the commitment and differentiation 
to slowly proliferating early erythroid progenitors (Burst-forming units-
erythroid, BFU-E) and then to rapidly proliferating late erythroid progenitors 
(colony-forming units-erythroid, CFU-E), which subsequently give rise to 
morphologically recognizable erythroid precursors (Erythroblasts)2. These 
early erythroblasts undergo a transient proliferative burst of about 4 divisions 
in 48 hours, along with decrease in cell size, increase in hemoglobin content 
and nuclear condensation, followed by exit from the cell cycle and 
enucleation3,4. The process by which the number of terminal maturation 
divisions is tightly controlled and coupled with the differentiation program is 
not well understood.    
 
1.1.1. Role of Erythropoietin 
 Erythropoietin (EPO) is the major cytokine controlling definitive erythroid 
maturation, and it plays important roles in activating erythroid specific genes, 
driving terminal proliferation and protection against apoptosis5. Introduction 
of null mutations in the genes for EPO or its receptor (EPOR) led to death of 
the homozygous null mice on embryonic day 13 (E13) due to failure of 
definitive fetal liver erythropoiesis6, but both BFU-E and CFU-E progenitors 
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were present in both these homozygous null fetal livers. This demonstrated 
that neither EPO nor the EPOR is required for erythroid lineage commitment 
or for progression from BFU-E to CFU-E stage, but both are essential for the 
survival, proliferation and terminal differentiation of the CFU-E progenitors6. 
EPO protects terminally differentiating erythroid cells from apoptosis by 
induction of the anti-apoptotic protein Bcl-XL7. The terminal maturation of 
committed erythroid progenitors has 2 phases: an EPO-dependent phase8 and 
an EPO-independent phase9. After the EPO responsive phase, the EPO 
receptors are progressively shed and the cells require signaling from 
fibronectin in the extra-cellular matrix for continued expansion of cell 
numbers. This increase in cell number is a result of protection from apoptosis 
by the integrin signaling from cell surface, resulting from interaction between 
alpha4beta1 integrins on the cell surface and the fibronectin in the extra-
cellular matrix9.  
 
An in vitro culture system containing EPO can support the proliferation and 
differentiation of primary erythroblasts in a manner that closely resembles the 
terminal erythroid differentiation in vivo10. In order to monitor erythroid 
differentiation, flow cytometry analysis of expression of the erythroid-specific 
cell surface marker TER119 and the transferrin receptor CD71 was used. The 
mouse fetal liver contained about 5 distinct populations based on TER119 and 
CD71 expression, named R1 to R5, which represented cells in consecutive 
stages of terminal erythroid maturation starting from early erythroblasts to 
enucleated reticulocytes. When TER119-negative erythroblasts were purified 
from fetal liver and cultured in vitro in medium containing erythropoietin on 
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fibronectin-coated plates, the erythroblasts underwent terminal proliferation 




Figure 1. An in vitro culture system that recapitulates the terminal erythroid 
differentiation and proliferation observed during in vivo erythroid development 
(A) Flow cytometry analysis of terminal erythroid differentiation in vivo. The total 
fetal liver cells obtained from mouse embryos in different stages of development 
(E12.5 to E15.5) were stained with PE-conjugated-TER119 and FITC-conjugated-
CD71 antibodies, and analyzed by flow cytometry. (B) Flow cytometry analysis of 
terminal erythroid differentiation in vitro. TER119-negative fetal liver erythroblasts 
were purified from E13.5 mouse embryos and cultured in erythropoietin containing 
medium in fibronectin-coated plates. Cells were harvested at 0 hours (Day 0), 24 
hours (Day 1) or 48 hours (Day 2) in culture. Differentiation states of the cells were 
analyzed by flow cytometry and benzidine-Giemsa staining. Figure republished from 
Zhang et al., Blood. 2003 Dec 1;102(12):3938-4610, with permission.  
 
1.1.2. Terminal cell division and cell cycle exit 
Mammalian erythroblasts are induced by erythropoietin to undergo rapid 
terminal differentiation divisions followed by a G1 phase cell cycle arrest. 
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This exquisitely regulated process controls the number of mature red blood 
cells produced in the body and maintains homeostasis of cell numbers. The 
regulatory mechanisms controlling the exact numbers of terminal 
differentiation divisions and the timing of cell cycle arrest is not well 
understood. In a study using friend virus infected non-transformed primary 
mice erythroblasts, accumulation of the cyclin-dependent kinase inhibitor 
(CDKI) P27Kip1 (p27) was associated with cell cycle exit during late stages of 
terminal maturation11. p27 accumulated as erythroid differentiation progressed 
and its expression peaked during late stages of erythroid maturation, 
suggesting that p27 is a key component of the cell cycle exit machinery. 
Studies using murine erythroleukemia (MEL) cells suggested that cell cycle 
withdrawal of differentiating erythroid cells is mediated by induction of 
several cyclin-dependent kinase inhibitors leading to the inhibition of CDK2 
and CDK412. 
 
 Knock-out mice experiments have provided important clues to the coupling 
between the cell cycle progression and differentiation in the erythroid lineage. 
P27Kip1-/- mice13-15, which are larger in body size than their normal wild type 
counterparts, have increased number of early erythroid progenitors in the bone 
marrow and spleen indicating the role of p27 in controlling the number of 
erythroid progenitors in the adult body15. There is no reported abnormality in 
the numbers and proportions of mature, enucleated red blood cells in the 
hematopoietic system of the p27 knockout mice, suggesting that p27 may not 




The retinoblastoma protein (Rb) is an important checkpoint in mammalian cell 
cycle progression, one of its functions being the negative regulation of E2F-
dependent transcription which drives cell cycle progression in mammals. Rb-
null mice16-18 fail to develop beyond E14.5 and the fetal liver consisted of 
large numbers early erythroid progenitors that failed to upregulate the 
erythroid-specific surface marker TER119 and enucleate. Further studies 
established that the role of Rb in terminal erythroid maturation was cell 
intrinsic19,20. Studies in Rb-/- E2f2-/- mice reported that the loss of E2F2 
restored terminal maturation and enucleation to Rb-null erythroblasts, 
demonstrating that Rb-E2F2 interaction is important during late stage 
erythroid maturation21. Furthermore, the E2f2-/- single null mice showed 
enlarged red cells in the peripheral blood indicating that the differentiating 
erythroid cells underwent a premature cell cycle exit. Taken together, these 
results indicate the presence of a precisely regulated cell cycle machinery 
controlling the late stage erythroid differentiation and cell cycle exit. Studying 
erythropoiesis in mice deficient for other key cell cycle proteins will elucidate 
the regulatory mechanisms controlling the terminal erythroid differentiation in 
mammals. 
 
1.1.3. Erythroid enucleation 
Late stage mammalian erythroblasts undergo chromatin and nuclear 
condensation, and enucleate by extrusion of the pycnotic nucleus surrounded 
by a thin layer of cytoplasm and cell membrane22-24. The molecular 
mechanisms that regulate this hallmark process remain to be fully elucidated. 
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Maturing erythroblasts are closely associated with macrophages in the blood 
islands25, indicating that interaction with macrophages might be critical for 
enucleation. Macrophages engulf the extruded erythroid nuclei after they are 
disconnected from the reticulocytes26 and macrophage deoxyribonuclease II 
(DNase II) has been proposed to be responsible for destruction of extruded 
erythroid nuclear DNA27. Although these post-enucleation roles for 
macrophages are indispensable for normal erythropoiesis, there is no evidence 
demonstrating a direct role for macrophages in the regulation of erythroid 
enucleation. Furthermore, erythroblasts can enucleate autonomously in culture 
without the need for contact with macrophages28,29. Caspase activation similar 
to apoptosis was shown to play a role in enucleation of lens epithelial cells30 
and keratinocytes31, the only other mammalian cell types known to undergo 
enucleation, suggesting that erythroid enucleation might also involve 
mechanisms similar to apoptosis. However, studies in cultured erythroblasts 
demonstrated that erythroid nuclear condensation and enucleation did not 
involve major activation of the classical apoptotic machinery32. We previously 
reported that Rac GTPases and their downstream effector mDia2 play 
important roles in the cytoskeletal reorganization leading to the extrusion of 
the pycnotic nucleus from late stage erythroblasts33. Nevertheless, the 
mechanism regulating condensation of the erythroid nucleus preceding its 
extrusion remains unclear. 
 
1.2.  c-Myc: Role in hematopoiesis and cancer 
One of many genes that play a role in regulating hematopoietic homeostasis is 
the proto-oncogene c-Myc (Myc). Myc has been widely studied since its 
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discovery 30 years ago as a cellular homolog of retroviral v-myc oncogene34,35. 
Further studies demonstrated that the proto-oncogene c-Myc was amplified in 
several animal and human tumours36,37. It is one of the most frequently 
activated oncogenes involved in human cancers, with 80% of breast cancers, 
70% of colon cancer, 90% of gynecological cancers, 50% of hepatocellular 
carcinomas and a variety of hematological tumors possessing abnormal Myc 
expression (http://www.myccancergene.org).  Despite early identification of 
its role in tumorigenesis, identifying the biological functions of Myc in its 
more important role as a transcription factor in normal cells has presented a far 
greater challenge. 
 
1.2.1. Myc transcription factor 
Myc encodes a basic-helix-loop-helix zipper (bHLHz) transcription factor that 
dimerizes with its partner Max38-40, itself another bHLHz protein. This 
heterodimer binds to the E-box sequence CACGTG in promoters of specific 
genes and stimulates their transcription41. The amino-terminal domain of Myc 
protein acts as a transcription activation domain42. Max also dimerises with the 
Mad family43 of proteins, a group of related bHLHz proteins, to act as Myc 
antagonists. Mad-Max dimers bind to Myc target promoters to repress 
transcription. The transcription activation by Myc at its target genes is at least 
partially mediated by recruitment of histone acetyltransferases such as Gcn544 
and Tip6045.  Myc has also been reported to repress transcription at certain 
target promoters46. The number of genes repressed by Myc is estimated to be 
similar to the number of genes activated by it, indicating an important role of 
repression in Myc functions. The molecular mechanism of Myc as a repressor 
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is not as well understood as that of Myc as a transcriptional activator.  The 
emerging model for Myc repression is that Myc-Max complexes interact with 
transcriptional activators bound to DNA through enhancer or initiator 
elements, and displace co-activators while recruiting co-repressors47-50. 
 
Several studies have demonstrated important roles for Myc in normal, non-
transformed cells in regulating proliferation, apoptosis and cell growth51-54. It 
is estimated that Myc binds to about 10-15% of the genes in the genomes from 
flies to humans51,55. Genomic studies have shown that Myc is a global 
regulator of transcription, and its target genes are involved in diverse functions 
such as cell cycle regulation, metabolism, ribosome biogenesis, protein 
synthesis and mitochondrial function51,56. Furthermore, Myc has been shown 
to regulate transcription mediated by all the three RNA polymerases51,57-59. 
 
The most well understood function of Myc is its ability to promote cell cycle 
progression60. Early studies established that mitogenic stimulation of quiescent 
cultured cells led to rapid induction of Myc mRNA61, indicating a role for 
Myc in promoting entry into the cell cycle. Both the mRNA and protein levels 
of Myc had extremely short half-lives62,63, and both were expressed at 
detectable steady state levels in cycling cells64,65. Myc-deficient rat fibroblasts 
generated by targeted homologous recombination were viable but showed 
greatly reduced proliferation rates66. Together, these data demonstrated that 
Myc is critical for normal cell cycle progression and is regulated in a manner 
that allows it to respond promptly to external proliferative cues such as 
mitogenic or serum stimulation. Several mechanisms of cell cycle regulation 
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by Myc have been uncovered over the years60,67. Myc promotes cell cycle 
progression by direct transcriptional activation of cyclin D268 and cyclin-
dependent kinase 4 (CDK4)69, which in turn leads to sequestration of the CDK 
inhibitor CDKN1B (P27Kip1 or p27) in the cyclin D2-CDK4 complexes. Myc 
directly represses the expression of CDK inhibitors CDKN1A (p21)70, 
CDKN1B (p27)71 and CDKN2A (p15)72. Myc also positively regulates the 
transcription of E2F173,74, E2F275 and E2F376, which are critical for normal 
cell growth and proliferation. The role of Myc in cell growth has been 
demonstrated by different groups in flies53 and mammals52, and this effect 
appears to be independent of its effect on cell proliferation. These studies also 
suggest that Myc might play an important role in coordinating cell growth and 
cell division in response to mitogenic signals. 
 
Induction of apoptosis by ectopic or deregulated Myc expression is an 
important function that plays a role in the biological outcome of Myc 
expression77-79. The Myc induced apoptotic response was suppressed in the 
presence of specific survival factors80, suggesting that the balance between the 
anti-apoptotic signals from the available survival factors and the apoptotic 
signals induced by Myc is critical in determining the cell survival. 
Transformed cells should have the ability to proliferate as well as overcome 
apoptosis induced by tumor suppressor pathways to develop into cancers. A 
widely accepted view is that deregulated Myc expression, like most oncogenes, 
promotes a hyperproliferative state that invokes the in-built tumor suppressor 
functions present in normal cells leading to cell death, and hence preventing 
the expansion of malignant cells. This notion is supported by the observation 
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that overexpression of anti-apoptotic proteins such as Bcl2 suppressed Myc-
induced apoptosis and aided cellular transformation81-83.  Several pathways 
have been implicated in Myc-induced apoptosis84-86, and the favored 
mechanism for induction of apoptosis by Myc may be determined by several 
factors such as cell type, availability of specific survival signals and presence 
of additional mutations. One of the mechanisms by which Myc potentiates 
apoptosis involves the activation of p53 tumor suppressor pathway87,88. Myc  
upregulates ARF, which in turn activates p53 leading to apoptosis89. The 
disruption of ARF-MDM2-P53 pathway of apoptosis by the loss of these 
tumor suppressors in mouse models of Myc oncogenesis accelerated 
tumorigenesis90-92, confirming the role of this pathway in mediating Myc-
induced apoptosis. Myc also triggers apoptosis by indirectly suppressing the 
anti-apoptotic proteins Bcl2 and Bcl-XL93-95. The pro-apoptotic protein BAX 
has been shown to play an important role in Myc induced apoptosis96,97, and 
loss of BAX diminished the induction of apoptosis by Myc in vivo98. A better 
understanding of the molecular mechanisms of Myc-induced apoptosis can 
lead to better therapies for tumors resulting from deregulated Myc, possibly by 
pharmacologically resurrecting the Myc-induced apoptotic pathways. 
 
1.2.2. Myc in cancer development and maintenance 
Since its identification as a cellular homolog of retroviral v-myc oncogene34,35, 
the functions of Myc pertaining to oncogenesis has been studied in detail. Myc 
regulates proliferation, differentiation and apoptosis- functions that are 
abnormal in transformed cells. Tumor cells proliferate without the requirement 
of external mitogenic signals, are poorly differentiated and override apoptosis. 
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Deregulated Myc expression is observed in a wide range of tumor types. 
Unlike other oncogenes such as Ras, where oncogene activation was due to 
mutations in the coding sequence, Myc did not display activating mutations. 
Instead, oncogenic activation of Myc is often established by insertional 
mutagenesis, chromosomal translocations or gene amplification67. Myc was 
the first oncogene identified to be activated by retroviral insertional 
mutagenesis99,100. Activation of Myc as a result of chromosomal translocations 
is commonly observed in hematopoietic tumors101. In contrast, activation of 
Myc by gene amplification is commonly seen in solid tumours like lung 
cancer102,103. Transgenic mice expressing the MycER fusion protein, where 
transcription by Myc can be functionally switched on by the addition of 4- 
hydroxytamoxifen (4-OHT), provided important clues on the effect of Myc 
activation in different tissues104,105. MycER activation induced post-mitotic 
keratinocytes to re-enter the cell cycle leading to epidermal hyperplasia105. In 
contrast, activation of Myc in pancreatic β cells showed apoptosis as the 
dominant outcome104. This demonstrated that the outcome of ectopic Myc 
expression depends on the cell type. Tumor results when the pro-apoptotic 
function of Myc is abrogated and the proliferation promoting function of Myc 
is dominant. 
 
The role of Myc in maintenance of tumors has been addressed by several 
transgenic models of Myc tumorigenesis. Using a tetracycline regulatable 
system, Myc expression was turned off in T-cell lymphomas and active 
myeloid leukemias106. Inactivation of Myc expression was sufficient to induce 
sustained tumor regression in majority of the mice, while 10% of the mice 
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relapsed with tumors and eventually died. These tumors that failed to regress 
may have attained additional mutations that removed the dependence of these 
tumors on Myc expression. Similar regression of tumors upon Myc 
inactivation has also been observed in case of solid tumors, such as benign 
angiogenic epidermal tumors105. Regression of Myc-induced mammary 
adenocarcinomas has also been demonstrated in a mouse model, where a 
subset of tumors failed to reverse and was identified to carry additional 
mutations in RAS107. These studies suggest that the Myc-induced tumors 
become dependent on Myc expression for their maintenance, a phenomenon 
known as “oncogene addiction”, and regress upon inactivation of Myc unless 
they have developed additional mutations over the course of time to substitute 
for their dependence on Myc. Further studies showed that even transient 
inactivation of Myc was sufficient for reversal of tumorigenic phenotype 
induced by Myc108. Subsequent reinduction of Myc in these led to apoptosis 
than tumorigenesis, suggesting that transient inactivation of Myc may provide 
an effective therapy for cancers resulting from deregulated Myc. 
 
1.2.3. Role of Myc in Hematopoiesis 
Myc plays several important roles in hematopoietic system development and 
disease109. Myc null embryos die between E9.5 and E10.5, and the embryos 
are smaller and delayed in development110. Subsequently, an allelic series of 
mice were developed in which Myc levels were incrementally reduced to 
zero111. The reduction of Myc levels in vivo led to multiorgan hypoplasia and 
smaller body size, suggesting that Myc plays an important role in determining 
the organ and body size in mammals by controlling the ability of the cells to 
 13 
divide111. Epiblast-specific deletion of Myc in mice demonstrated that both 
primitive and definitive hematopoiesis is impaired in the absence of Myc112. 
This study also established that physiological levels of Myc are essential for 
cell survival, and that erythroblasts and hematopoietic progenitors are 
particularly dependent on Myc function. 
 
Alterations in Myc expression are associated with several hematological 
malignancies101,113. It is well established that Myc is expressed in almost all 
proliferating cells and its repression is associated with terminal differentiation 
of many cell types including the myeloid lineage114. Deregulated expression of 
Myc in the myeloid cells in mouse bone marrow and also in myeloid leukemic 
cells block the terminal differentiation and prevents proliferation arrest in 
these cells115. These cells proliferated at a much slower rate because of the 
induction of a P53-independent apoptotic pathway whose effect was not 
completely penetrant across the entire population of cells. In a recent study, it 
was shown that Myc over-expression caused myeloid progenitors to develop 
into acute myeloid leukemia, without any requirement for anti-apoptotic 
mutations that are needed in the case of lymphoid leukemogenesis116. This 
study indicates that the tumorigenic potential of Myc depends on the cell type 
and the developmental stage of the target cells.  
 
The role of Myc is not limited to driving the self renewal of the hematopoietic 
progenitor cells. In hematopoietic stem cells (HSC), Myc controls the balance 
between proliferation and differentiation117,118. Conditional elimination of Myc 
in the bone marrow cells lead to severe cytopenia and accumulation of HSCs 
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in the bone marrow117,118. The differentiation of HSCs was severely impaired, 
leading to a marked decrease in the number of myeloid and lymphoid cells. 
Unexpectedly, forced expression of Myc was shown to induce HSC 
differentiation at the expense of self renewal117, suggesting that the role of 
Myc in the hematopoietic lineage is not limited to promoting proliferation, and 
that Myc levels can be important determinants of cell fates and differentiation. 
 
1.3.  Motivation of the thesis 
Mammalian terminal erythroid development is a precisely regulated process 
involving rapid proliferation and serial morphological changes of committed 
erythroid progenitors (colony forming units-erythroid, or CFU-E) to form 
mature erythrocytes. The initial stages of terminal erythroid maturation are 
highly dependent on erythropoietin, whose roles in activation of erythroid 
specific genes, terminal proliferation and protection against apoptosis are well 
understood. Upon erythropoietin stimulation, CFU-E progenitors undergo 4-5 
cell divisions accompanied by decrease in cell size, increase in hemoglobin 
content and nuclear condensation, followed by exit from the cell cycle and 
extrusion of the inactive nucleus. The regulation of the late-stage erythroid 
maturation events such as cell cycle arrest and enucleation is not well 
understood. The expression of Myc was downregulated during late stages of 
erythroid maturation coinciding with the cell cycle arrest and enucleation, 
suggesting that Myc may regulate on or both of these processes. The 
physiological relevance of these noticeable changes in Myc expression during 
terminal erythroid maturation remained unclear due to conflicting reports in 
literature119,120. Studies in G1E erythroid cell lines report that forced Myc 
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expression prevented cell cycle arrest but had minimal effects on erythroid 
maturation119. In contrast, Myc expression blocked erythroid differentiation in 
human Leukemia K562 cells without overriding the cell cycle arrest120. These 
discrepancies were possibly a result of the different cell lines used as models 
of terminal erythroid maturation, prompting us to investigate the role of Myc 
in terminal erythroid differentiation using primary erythroid progenitor cells. 
In this study, we used a recently developed in vitro culture system, in which 
the differentiation of purified TER119-negative mouse fetal liver erythroblasts 
can be monitored quantitatively in a step-by-step manner, to investigate the 
role of Myc in terminal erythroid maturation.  
 
In this thesis, we demonstrate that ectopic Myc expression has a dose-
dependent effect on terminal erythroid differentiation of purified mouse fetal 
liver erythroblasts cultured in vitro. Ectopic Myc expression at physiological 
levels specifically blocks enucleation without affecting terminal erythroid 
maturation, while overexpression of Myc at levels above the physiological 
range promotes proliferation of the erythroblasts at the expense of 
differentiation as well as evoking an apoptotic response. Our study indicates 
that Myc levels play a critical role in regulating the balance between 
proliferation and differentiation in the erythroid lineage. Our data uncovers an 
important role for Myc in erythroid nuclear condensation and enucleation, and 





CHAPTER 2 – MATERIALS AND METHODS 
2.1. Purification and culture of mice fetal liver erythroid progenitors  
All mouse work was carried out with approved Institutional Animal Care and 
Use Committee (IACUC) protocols at the Biological Research Centre (BRC) 
mouse facility at Biopolis. Fetal livers were isolated from E13.5 C57BL/6 
mice embryos and mechanically dissociated by pipetting in PBS containing 
20% fetal bovine serum (FPBS). The dissociated cells were passed through 70 
and 30 micron strainers to obtain single-cell suspensions. For negative 
selection, cells were labeled with magnetic microbead-conjugated antibodies 
for TER119 and CD11b (to remove macrophages) and passed through LD 
columns according to the manufacturer’s instructions (Miltenyi Biotec). 
Briefly, the cells were resuspended in 700 μL FPBS in a 50 ML falcon tube. 
200 μL of TER119 microbeads (Miltenyi Biotec, # 130-049-901) and 100 μL 
of CD11b microbeads (Miltenyi Biotec, # 130-049-601) were added to the cell 
suspension, mixed gently without formation of air bubbles, and incubated at 
4 °C in a refridgerator for 15 minutes. Meanwhile, LD columns (Miltenyi 
Biotec, # 130-042-901) were placed in the magnet stand and were equilibrated 
by adding 2 mL FPBS to the columns and allowing it to flow through. After 
incubation, the cell suspension was passed through the LD columns. The 
column was washed with 2 x 1 mL of FPBS and the total effluent was 
collected as the TER119-negative CD11b-negative cells. The cells were 
pelleted by centrifugation at 2000 rpm for 5 minutes, and resuspended in 
erythropoietin containing media for in vitro culture.   
 
 The purified TER119-negative erythroblasts were seeded in fibronectin-
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coated plates and cultured in Iscove’s modified Dulbecco medium (IMDM, 
Invitrogen) containing 15% FBS (StemCell Technologies, Catalog no: 06250),  
1% detoxified bovine serum albumin (StemCell Technologies, Catalog no: 
#09300), 200 μg/mL holo-transferrin (Sigma, T0665),10 μg/mL recombinant 
human insulin (Sigma, 91077C), 2mM L-glutamine (Invitrogen), 10-4M β-
mercaptoethanol (Invitrogen), and 2U/mL erythropoietin (R&D systems).  For 
p27 knockout studies, E13.5 embryos harvested from intercrosses of p27+/- 
mice13 were genotyped as described previously121, followed by purification of 
fetal liver erythroid progenitors. 
 
2.2. Cloning of retroviral constructs 
The murine stem cell retroviral vector (MSCV) construct that co-expresses 
Myc and GFP (MSCV-Myc-IRES-GFP) was a gift from Dr. Michael H. 
Tomasson116. The MSCV-MycER-IRES-GFP construct to over-express 
MycER was provided by Dr. John L. Cleveland95. Retroviral construct 
expressing shRNA against c-Myc were purchased from Open Biosystems. The 
target sequence for c-Myc shRNA is 5’ AGCCTTGAAATGTAAATAACTT 
3’ and the target sequence of the non-silencing negative control (incomplete 
luciferase shRNA) is 5' GTGCGTTGCTAGTACCAACTTCAAGAGA 3'.  
 
The MSCV-Gcn5-IRES-GFP construct to overexpress Gcn5 was made by 
cloning the full length Gcn5 open reading frame (ORF) into the EcoRI-NotI 
sites of MSCV-IRES-GFP vector. The full length GCN5 ORF was PCR 
amplified from cDNA clones provided by Dr Sharon Y.R. Dent122, using the 
following primers:   
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GCN5 Forw:  5' GGGGAATTCgccaccATGGCGGAACCTTCCCAGG 3' 
GCN5 Rev: 5' 
GATATATAGCGGCCGCCTACTTGTCGATGAGCCCTCCCTC 3' 
The annealing temperature used for the PCR was 63 °C. 
 
The MSCV-Elp3-IRES-GFP construct to overexpress Elp3 was made by 
cloning the Elp3 ORF into the Xho1-EcoR1 site of MSCV-IRES-GFP vector. 
The full length Elp3 ORF was PCR amplified from cDNA library prepared 
from E13.5 mice fetal liver cells, using the following primers: 
Elp3 Forw: GACTCGAgccaccATGAGGCAAAAGAGGAAAGGG 
Elp3 Rev: CGGAATTCTTATTTTAGCATCTTTACCATGTAGGG 
The annealing temperature used for the PCR was 55 °C. 
 
The MSCV-Hat1-IRES-GFP construct was made by cloning the Hat1 ORF 
into the Xho1-EcoR1 site of MSCV-IRES-GFP vector. The full length Hat1 
ORF was PCR amplified from cDNA library prepared from E13.5 mice fetal 
liver cells, using the following primers: 
Hat1 Forw: GACTCGAgccaccATGGCGGCCTTGGAGAAATT 
Hat1 Rev: CGGAATTCTCACTCTTGAGCAAGTCGCTCAAT 
The annealing temperature used for the PCR was 55 °C. 
 
The MSCV-Pcaf-IRES-GFP construct was made by cloning the Pcaf ORF into 
the BglII-NotI site of MSCV-IRES-GFP vector. The full length Hat1 ORF was 
PCR amplified from the cDNA clone MMM1013-9498151 (Open Biosystems), 
using the following primers: 
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PCAF forw1_BamHI: CGCGGATCCgccaccATGGCCGAGGCTGGCG 
PCAF rev1_NotI: 
GATATATAGCGGCCGCTCACTTGTCAATCAACCCTGCTTC 
The annealing temperature used for the PCR was 60 °C. 
 
The MSCV-Tip60-IRES-GFP construct was made by cloning the ORFs for 
Tip60 alpha- and beta- isoforms into the EcoRI-NotI site of MSCV-IRES-GFP 
vector. The full length Tip60 ORF was PCR amplified from pBabe clones 
provided by Dr. Iver Nordentoft123. The primers used for PCR are as follows: 
TIP60 forw: GGGGAATTCgccaccATGGCGGAGGTGGGGGA 
TIP60 rev: GATATATAGCGGCCGCTCACCACTTTCCTCTCTTGCTCCA 
The annealing temperature used for the PCR was 62 °C. 
 
The MSCV-CBP-IRES-GFP construct was made by cloning the full length 
CBP ORF into the BglII-NotI sites in the MSCV-IRES-GFP vector. The CBP 
ORF was PCR amplified from the pRC/RSV-mCBP-HA clone provided by 
Dr. Richard Goodman124, using the following primers: 
CBP forw: GAAGATCTgccaccATGGCCGAGAACTTGCTGG 
CBP rev: GATATATAGCGGCCGCCTACAAACCCTCCACAAACTTTTC 
The annealing temperature used for the PCR was 57 °C. 
  
The MSCV-p300-IRES-GFP construct was made by cloning the full length 
CBP ORF into the XhoI-NotI sites in the MSCV-IRES-GFP vector. The p300 
ORF was PCR amplified from the cDNA clone EMM1002-99866371 (Open 
Biosystems) using the following primers: 
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P300 forw: GACTCGAgccaccATGGCCGAGAATGTGGTGG 
P300 Rev: 
GATATATGCGGCCGCCTAGTGTATGTCTAGTGTACTCTGTGAGAGG 
The annealing temperature used for the PCR was 57 °C. 
 
The MSCV-cyclinD1-IRES-GFP construct was made by cloning the cyclin D1 
ORF into the BglII-EcoRI site of MSCV-IRES-GFP vector. The full length 
cyclin D1 ORF was PCR amplified from cDNA library prepared from E13.5 
mice fetal liver cells, using the following primers: 
Cyclin D1 Forw: GAAGATCTgccaccATGGAACACCAGCTCCTGTG 
Cyclin D1 Rev: CGGAATTCTCAGATGTCCACATCTCGCA 
The annealing temperature used for the PCR was 54 °C. 
 
2.3. Retrovirus generation and infection 
Replication-incompetent retroviruses were produced by co-transfection of 
293T cells with the MSCV constructs and the ecotropic packaging vector 
pCL-Eco using Lipofectamine 2000 (Invitrogen). Retroviral supernatants were 
harvested 48 hours after transfection, passed through 0.45 μm filters and 
stored in aliquots at -80 °C. The virus titers for the MSCV retroviral 
supernatants were estimated by transduction of NIH3T3 cells and quantifying 
the percentage of GFP-positive cells by FACS analysis. For infection of 
purified TER119-negative erythroid progenitor cells, 5 x 105 cells were 
resuspended in 1mL retroviral supernatant containing 8 μg/mL polybrene 
(Sigma) and centrifuged at 2000 rpm for 1hour at 37 °C. The virus supernatant 
was then replaced by erythropoietin containing medium. 
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2.4. Immunostaining and Flow cytometry  
Cells were washed and resuspended in 200 μL PBS containing 4% FBS for 
immunostaining. For analysis of erythroid differentiation, cells were incubated 
with 1:200 dilution of PE-conjugated anti-CD71 (BD Biosciences) and APC- 
conjugated anti-Ter-119 antibody (BD Biosciences) for 15 minutes at room 
temperature. For enucleation analysis, cells were additionally stained with 
10μg/mL Hoechst 33342 (Sigma) at room temperature for 15 minutes. 
Propidium Iodide (PI, BD Biosciences) at a final concentration of 0.2 μg/mL 
was added to exclude dead cells from the analysis. Apoptosis was evaluated 
by co-staining with APC-conjugated Annexin V (BD Biosciences) and PI. To 
perform cell cycle analysis, the cells were washed and resuspended in 50 μL 
PBS, fixed in 1mL cold 90% ethanol, and stored at 4°C overnight. The fixed 
cells were washed and incubated in PBS containing PI (20 μg/mL) and RNase-
A (200 μg/mL) for 1 hour at room temperature. Flow cytometry was 
performed using BD LSRII (BD Biosciences) and data analysis was carried 
out using BD FACSDiva (BD Biosciences). 
 
2.5. Benzidine-Giemsa staining  
5x104 cells were centrifuged onto glass slides using Cytospin 4 (Shandon). 
The cells were air dried completely and fixed in -20 °C methanol for 2 minutes. 
Benzidine solution was prepared by dissolving one benzidine tablet (Sigma, 
D5905) in 10mL PBS and filtered through a 0.22 micron filter. 10 μL of 30% 
Hydrogen peroxide solution (Calbiochem) was added to the Benzidine 
solution just before staining, and placed as drops directly on fixed cells for 2 
hours at room temperature. The cells were rinsed briefly with PBS and stained 
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with 1:20 dilution of Giemsa (Sigma, GS500) in water for 15 minutes at room 
temperature. Excess Giemsa stain was removed by washing with PBS.   
Images were captured on an Olympus BX51 microscope equipped with an 
Olympus DP70 digital camera using DPController image capture software 
(Olympus). 
 
2.6. Hemoglobin Assay  
1x106 erythroid cells were lysed in 200 μL Drabkin’s reagent (Sigma, D5941) 
and hemoglobin content was quantified by spectrophotometric measurement 
of absorbance at 540nm on a Tecan Sunrise Reader. 
 
2.7. Measurement of nuclear size  
Erythroid cells were fixed in 3.7% formaldehyde in PBS for 7 minutes at room 
temperature, and then incubated in 10 μg/mL Hoechst 33342 in PBS for 15 
minutes to stain the nucleus followed by 2 washes with PBS. The cells were 
resuspended in PBS and transferred to flat bottom 96-well cell culture plates, 
and centrifuged at 1000 rpm for 3 minutes to deposit the cells as a single layer 
at the bottom of the wells. Images were acquired by the automated Arrayscan 
VTI high content screening reader (Cellomics) using a 20X objective lens 
from 16 different fields in each well. The images were analyzed by Cellomics 
Target Activation BioApplication software. Cell clumps and debris were 
excluded from analysis by setting appropriate cut-off values after visual 
inspection of the images and data acquired consisted of at least 5000 objects 
(cells) per sample. The nuclear size (nuclear area per cell) for each sample was 
determined as the average Hoechst area per object in the sample. 
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2.8. Quantitative real-time polymerase chain reaction (qRT-PCR)  
Total RNA was extracted from cells using RNeasy mini kits (QIAGEN). 1 μg 
of total RNA for each sample was reverse transcribed using the High Capacity 
cDNA Archive Kit (Applied Biosystems). Relative transcript levels of 
different genes were quantified by SYBR green real time PCR using ABI 
Prism 7900HT Sequence Detection System 2.2 (Applied Biosystems). The 
results were normalized to GAPDH and analyzed using SDS 2.2.2 software. 
The qRT-PCR primer sequences were obtained from the PrimerBank125,126 
website (http://pga.mgh.harvard.edu/primerbank), or previous studies127, or 
were designed using the Primer Express 3.0 software (Applied Biosystems). 
The primer sequences used in qRT-PCR are as follows: 
 
Table 1. qRT-PCR primer sequences  
Erythroid differentiation genes 
Gene  Sense primer Antisense primer 
Hbb-b1 GCACCTGACTGATGCTGAGAA TTCATCGGCGTTCACCTTTCC 
Hbb-b2 GCACCTGACTGATGCTGAGAA ACTTCATCGGGGTTCACCTTT 
Hba-a1 CACCACCAAGACCTACTTTCC CAGTGGCTCAGGAGCTTGA 
Spna-1 AGAAATCCAACACCGAAGAGC TCCAGGTCATCTGCGTCTCTC 
gypA ACTGTAGGTAACCCAAATCAGCA GGAAAATCGTGTTGCACTTCAG 
GATA1 TGGGGACCTCAGAACCCTTG GGCTGCATTTGGGGAAGTG 
EKLF AGACTGTCTTACCCTCCATCAG GGTCCTCCGATTTCAGACTCAC 
 
Histone deacetylases (HDACs) 
Gene  Sense primer Antisense primer 
Hdac1 GGTCTCTACCGAAAAATGGAGA TCATCACTGTGGTACTTGGTCA 
Hdac2 CTCCACGGGTGGTTCAGT CCCAATTGACAGCCATATCA 
Hdac3 TCAACGTGGGTGATGACTG TGTTGCTCCTTGCAGAGATG 
Hdac4 AATCCTGCCCGTGTGAAC GTAGGGGCCACTTGCAGA 
Hdac5 GAGTCCAGTGCTGGTTACAAAA TACACCTGGAGGGGCTGTAA 
Hdac6 GAAGGAGGAGCTGATGTTGG TCATGTACTGGGTTGTCTCCAT 
Hdac8 GCAGCTGGCAACTCTGATT GTCAAGTATGTCCAGCAACGAG 
Hdac10 CGACTGCTCTGGGATGACCC CAGGCACCTTTCTTCCAGGC 
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Histone acetyltransferases (HATs) 
Gene  Sense primer Antisense primer 
Crebbp GGCTTCTCCGCGAATGACAA GTTTGGACGCAGCATCTGGA 
Elp3 CAGTCCCTCCTCACTATCGAA TCTGTGGGGTTTGCACATCAC 
Ep300 CAGAACCAGCAGATGCTCAA GAGGTGCTTGGCTGTTCTTC 
GCN5 AAGGCCAATGAAACCTGCAAG CTCACAGCTACGGCACAACTC 
Hat1 AAGTGTAACACCAACACAGCA CGAAAGCAGTTTCATCATCCCC 
PCAF  CGGATCGCCGTGAAGAAGG CATTGCATTTACAGGACTCCTCT 
Tip60  CGAGCGGCTGGACTTAAAGAA GGGCGGGACCCAGGAA 
 
Erythropoietin signaling genes 
Gene  Sense primer Antisense primer 
Prkcd TGGGGGTGACCTGATGTTC CCAGCACCAACAATACCTGTAA 
Jak2 TTGTGGTATTACGCCTGTGTATC ATGCCTGGTTGACTCGTCTAT 
Akt3 TGGGTTCAGAAGAGGGGAGAA AGGGGATAAGGTAAGTCCACATC 
Bcl-XL GACAAGGAGATGCAGGTATTGG TCCCGTAGAGATCCACAAAAGT 
Rac2 GACAGTAAGCCGGTGAACCTG CTGACTAGCGAGAAGCAGATG 
Ccng2 CCCCGGAGAATGATAACACTTT CCACTTTGGCATTTCTCAGTCT 
Hras CGTGAGATTCGGCAGCATAAA GACAGCACACATTTGCAGCTC 
 
Other cell cycle-related genes 
Gene  Sense primer Antisense primer 
ccne1 GTGGCTCCGACCTTTCAGTC CACAGTCTTGTCAATCTTGGCA 
Ebp1 CAGCAGGAGCAAACTATCGC GGCATCACCTTTCTCACACAAG 
cdc25a ACAGCAGTCTACAGAGAATGGG GATGAGGTGAAAGGTGTCTTGG 
Rac1 GAGACGGAGCTGTTGGTAAAA ATAGGCCCAGATTCACTGGTT 
mDia1 GCCAAGAATGAAATGGCTTCTC TAACAGTGCCAGAGTCACCAGG 
mDia2 AAGCTTCTGTCTGCAGTGTGCA GAGGCCTTCCACAATGGAAAA 
 
 
2.9. Gene expression microarrays and data analysis  
Total RNA was extracted from 3 biological replicates of the cells under each 
condition with RNeasy mini kits and 500ng was reverse transcribed into 
cDNA followed by in vitro transcription to biotin-labeled cRNA using the 
Illumina TotalPrep RNA Amplification kit (Applied Biosystems). 750 ng of 
each cRNA sample was hybridized to MouseRef-8 v2.0 Expression BeadChip 
microarrays (Illumina) and scanned on the BeadArray Reader (Illumina) at 
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scan factor 1. Background subtraction was applied on raw intensity values and 
subsequent data was subjected to quantile normalization on the Beadstudio 
Data Analysis platform (Illumina) with a normalized expression value cutoff 
at 100. Differentially expressed genes were identified based on an at least 2-
fold change in at least one condition compared to controls. Individual gene 
lists were uploaded into Ingenuity Pathway Analysis software (Ingenuity 
System) to identify the significantly enriched gene ontology categories based 
on molecular and cellular functions. The significance of the association 
between the dataset and the canonical pathway was measured and displayed in 
2 ways: ratio of the number of genes from the data set that map to the pathway 
divided by the total number of genes that map to the canonical pathway, and 
Fischer’s exact test was used to calculate a p-value determining the probability 
that the association between the genes in the dataset and the canonical 
pathway is explained by chance alone. Microarray data was deposited into 
Gene Expression Omnibus (accession number: GSE18558). 
 
2.10. Western Blotting 
Cells were lysed in RIPA buffer (Pierce) containing protease inhibitors 
(Roche). 20μg of total protein for each sample was resolved on a 10% SDS 
polyacrylamide gel and transferred to methanol-activated PVDF membranes 
(GE healthcare). After washing once with TBST (20 mM Tris, pH 7.5, 500 
mM NaCl, 0.1% Tween 20), the membranes were blocked for 1 hour at room 
temperature in 5% bovine serum albumin (BSA) in TBST with mild shaking.  
The blots were then incubated with primary antibody at appropriate dilution in 
TBST with 2% BSA overnight with gentle shaking at 4 °C, washed 3 times for 
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15 minutes with TBST and incubated with horseradish peroxidase-conjugated 
secondary antibody for 1 hour at room temperature. The blots were washed 
with TBST 3 times for 5 minutes and visualized using a chemiluminescent 
substrate (Luminol reagent, Santa Cruz Biotechnologies).  
 
Histones were purified by acid extraction for Western blot analysis of histones 
H3 and H4 acetylation. Cells were washed once with ice cold PBS and cell 
pellets were incubated in PBS containing 0.5% Triton X-100 and protease 
inhibitors for 10 minutes on ice. Pellets were resuspended in 0.2 N HCl at 4°C 
overnight for extraction of histones. The acidic pH of histone extracts was 
neutralized with 1 M Tris, pH 8. Equal loading of histones was ensured by 
Ponceau staining before proceeding for immunoblotting with acetylation-
specific antibodies.  
 
Primary antibodies used for Western blotting were as follows: Myc (SC-764, 
Santa Cruz). p27 (610241, BD Biosciences). GAPDH (ab37187, Abcam). 
Total histone H4 (ab10158, Abcam). The antibodies for H3K9Ac, H3K18Ac, 
H3K23Ac and H3 (total) were purchased from Cell signaling (#9927). 
Antibodies for H4K5Ac, H4K8Ac, H4K12Ac and H4K16Ac were purchased 







2.11. Chromatin Immunoprecipitation (ChIP) assay  
TER119-negative mouse fetal erythroid progenitor cells were purified from 
E13.5 mice fetal livers. About 5 x 107 – 1 x 108 cells were resuspended in 10 
mL PBS containing 20% FBS (FPBS) in a 10cm dish. 280 μL of 37% 
formaldehyde (Sigma, F8775) was added to the cell suspensions and swirled 
gently, followed by incubation at room temperature for 10 minutes for cross-
linking. At the end of 10 minutes, 500 μL of 2.5M glycine was added to the 
cells and swirled. The cells were spun down at 2500 rpm for 10 minutes at 
4 °C. The cells were washed twice by resuspending in 10 mL PBS followed by 
centrifugation at 2500 rpm for 10 minutes at 4 °C. After the final spin, the 
liquid was completely removed and the cell pellet was snap frozen in liquid 
nitrogen and stored at -80 °C. The chromatin immunoprecipitation was 
performed according to Agilent ChIP-on-chip protocol (version 9.1, Nov 
2006). Dynabeads Protein G magnetic beads (Invitrogen, 100.04D) were 
bound with 10 μg anti-c-Myc antibody (SC-764, Santa Cruz) at 4 °C overnight. 
Crosslinked cells were lysed with lysis buffer 1 (50 mM HEPES pH 7.3, 140 
mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, and 0.25% Triton X-
100) and washed with lysis buffer 2 (10 mM Tris-HCl pH 8.0, 200 mM NaCl, 
1 mM EDTA pH 8.0 and 0.5 mM EGTA pH 8.0). The nuclei were 
resuspended and sonicated in lysis buffer 3 (10 mM Tris-HCl pH 8.0, 100 mM 
NaCl, 1 mM EDTA pH 8.0, 0.5 mM EGTA pH 8.0, 0.1% Na-Deoxycholate 
and 0.5% N-lauroylsarcosine), with sonication cycles optimised to achieve 
final DNA size in the range of 300-500 bp. Triton X-100 was at a final 
concentration of 1% to the sonicated lysates and cleared by centrifugation. 50 
μL of the sonicated lysates were stored as whole cell extracts (WCE) and the 
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rest was incubated overnight at 4°C with antibody-bound magnetic beads to 
enrich for DNA fragments bound by Myc. The next day, magnetic beads were 
washed four times with RIPA buffer (50 mM HEPES pH 7.3, 500 mM LiCl, 1 
mM EDTA, 1% NP-40 and 0.7% Na-Deoxycholate) and once with TE 
containing 50 mM NaCl. Bound complexes were eluted in elution buffer (50 
mM Tris-HCl pH 8.0, 10 mM EDTA pH 8.0, 1% SDS) at 65°C for 15 min 
with occasional vortexing on a thermomixer. Crosslinks were reversed by 
overnight incubation at 65°C. RNA and protein were digested using RNase A 
and Proteinase K, respectively, and DNA was purified with phenol chloroform 
extraction and ethanol precipitation. The enrichments of binding sites in the 
immunoprecipitated DNA were quantified using qRT-PCR. The fold 
enrichment values were calculated by determining the apparent 
immunoprecipitation efficiency (ratios of the amount of immunoprecipitated 
DNA to that of the input sample) and normalized to the level observed at a 
control region, which was defined as 1.0.  The ChIP qRT-PCR primer 
sequences are as follows: 




Sense primer Antisense primer 
-1596 to -1690 CACTCTACCAGTGAGGCTGCT AGCGAAACCTTGGGCATC 
-44 to -142 CGATGGGAGTCGTAGTCTTCC GCTCAACCAAGCGACATTTG 
-3 to -96 GCAACCGGCGCACAG GTATGGAAGGCCAAAGGATG 
 
2.12. Statistical analysis 
Student’s t-test was used to determine the significance of differences between 
treated samples and controls. Statistical analysis was performed using 
Microsoft Office Excel 2003. 
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CHAPTER 3 – RESULTS  
 
3.1. In vitro culture of mice fetal erythroblasts and quantitative analysis 
of terminal differentiation 
In order to investigate the role of Myc in mammalian terminal erythroid 
differentiation, we used a recently developed in vitro culture system, in which 
the differentiation of purified TER119-negative mouse fetal liver erythroblasts 
can be monitored quantitatively in a step-by-step manner10. Embryonic day 
13.5 (E13.5) mice fetal liver was used as the source of erythroid progenitors 
since 90 percent of these cells belong to the erythroid lineage. In order to 
purify mice fetal liver erythroblasts, TER119-positive mature erythroid cells 
and CD11b-positive macrophages were depleted from E13.5 mice fetal liver 
cells. These TER119-negative erythroblasts were grown in erythropoietin 
containing medium on fibronectin-coated plates for 2 days, during which they 
recapitulate their normal terminal differentiation, proliferation and enucleation 
in vitro. Our lab has previously shown that the erythroid differentiation of the 
purified fetal erythroblasts in vitro when grown under our culture conditions, 
perfectly reflects the erythroid differentiation in vivo10, making this a very 
good model system to investigate mammalian erythropoiesis. Retroviral 
vectors were used to over-express genes or shRNAs in these purified 
eythroblasts to study their effect on the various aspects of terminal erythroid 
maturation, which is difficult to accomplish in vivo.  In order to analyze these 
changes quantitatively, we defined various parameters for terminal erythroid 
maturation and the assays to monitor and measure them (Table 3). 
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Table 3. Quantitative assays to monitor terminal erythroid differentiation 




   parameter 
 
 Changes during terminal 
 erythroid maturation 
 
  Assays 
   
 
Surface marker                          
expression 
 
Ter-119 increases, CD71 
increases and then decreases. 
 
  





Decreases from about 20 µm 




 Forward scatter in Flow 




condensation      
 
  
The nucleus condenses 




 Benzidine-Giemsa  
 staining, Immunostaining 







After the terminal maturation 
divisions, the late stage 




 Flow Cytometry,  





The erythroblasts undergo ~4 
terminal cell divisions in 2 days  
 
 
  Manual counting using  
hemocytometer 
 




The erythroblasts arrest in the 
G1 phase of cell cycle at the 




 Cell cycle analysis by flow 
 cytometry 
 




The hemoglobin expression 
increases with the progress of  
terminal maturation  
 
 
 Benzidine-Giemsa  




3.2. Ectopic Myc expression has a dose-dependent effect on terminal 
erythroid maturation 
As a first step in addressing the role of Myc in terminal erythropoiesis, we 
monitored the changes in Myc protein levels during differentiation of 
TER119-negative erythroid progenitor cells purified from E13.5 mouse fetal 
livers and cultured for 2 days in vitro. Myc protein levels decreased 
substantially during the course of in vitro differentiation (Figure 2A, lanes 1-3). 
We also quantified changes in p27Kip1 (p27) protein levels since p27 is 
repressed by Myc71 and changes in p27 levels has been suggested to play a 
critical role in the withdrawal from cell cycle during terminal erythroid 
maturation11. As expected, p27 protein levels were strongly induced during the 
later stages of erythroid differentiation (Figure 2A, lanes 1-3). 
 
We then examined differentiation of TER119-negative erythroid progenitor 
cells ectopically expressing Myc. A bicistronic retroviral vector (MSCV-Myc-
IRES-GFP) that also encodes green fluorescent protein (GFP) was used to 
express Myc in purified TER119-negative erythroid progenitor cells. This 
allowed for GFP intensity measured by flow cytometry to serve as a reporter 
for the level of ectopic Myc expression128. At 24 hours post-retroviral 
infection, the cells were sorted based on GFP intensity into low GFP (Myc-
GFPlow) and high GFP populations (Myc-GFPhigh), followed by culture for 
another 24 hours to allow for complete terminal maturation. Cells infected 
with retroviruses encoding GFP only (MIG) served as control. Western blot 
analysis of retrovirus transduced cells was performed at 24 and 48 hours post-
infection to measure Myc and p27 levels (Figure 2A, lanes 4-9), and were 
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compared with those during differentiation of uninfected erythroblasts (Figure 
2A, lanes 1-3). The Myc-GFPlow cells showed continued Myc expression at 
levels similar to those of normal cells at 1 day of differentiation (Figure 2A, 
lanes 5 and 8), and thus within a physiological range. In contrast, the Myc-
GFPhigh cells demonstrated Myc protein levels greater than early erythroid 
progenitors (freshly purified TER119-negative fetal liver erythroblasts) at both 
24 and 48 hours in culture, indicating that these cells represented high-level 
Myc-overexpressing erythroblasts. (Figure 2A, lanes 6 and 9).   At 48 hours in 
culture, the induction of p27 in Myc-GFPlow cells was similar to that of 
control, but p27 induction was significantly reduced in Myc-GFPhigh cells 
(Figure 2A, lanes 7-9). 
 
Next we assayed the terminal differentiation states of Myc-GFPlow, Myc-
GFPhigh and control (MIG) cells by flow cytometry at 48 hours in culture. 
The percentage of CD71+TER119+ populations were similar in Myc-GFPlow 
and control cells but were significantly reduced in the Myc-GFPhigh cells, 
suggesting that overexpression of Myc at high levels blocked erythroid 
differentiation (Figure 2B, Top panel). Enucleation was quantified by 
measuring the reticulocytes formed in culture, which stain positive for the 
erythroid differentiation marker TER119 and negative for Hoechst 33342 
(Hoechst). The TER119+ Hoechst- reticulocyte population seen in the control 
cells was absent in both Myc-GFPlow and Myc-GFPhigh cells (Figure 2B, 
Middle panel), indicating that sustained expression of Myc even at a 
physiological level was sufficient to block erythroid enucleation. Myc-
GFPlow cells did not show any significant change in the levels of apoptosis 
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compared to control cells, whereas Myc-GFPhigh cells showed significantly 
high amounts of apoptosis (Figure 2B, Bottom Panel). Taken together, 
continued expression of Myc at a physiological level blocked enucleation 
specifically without affecting the terminal differentiation or survival of 
primary erythroblasts, while overexpression of Myc at supraphysiological 














                 
Figure 2. Dose-dependent effect of ectopic Myc on terminal erythroid 
maturation. (A) Western blot analysis of Myc and p27 protein levels. TER119-
negative fetal liver erythroblasts purified from E13.5 mouse embryos and cultured in 
erythropoietin containing medium in fibronectin-coated plates and cells were 
harvested at 0 hours (D0), 24 hours (D1) or 48 hours (D2) in culture. Purified 
erythroblasts were infected with bicistronic retroviruses encoding GFP only as control, 
or both Myc and GFP at 0 hours in culture. At 24 hours post infection, cells were 
sorted based on GFP intensity into low (Myc-GFPlow) and high (Myc-GFPhigh) 
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intensity populations, then cultured for another 24 hours to allow for differentiation. 
Cells were harvested at indicated time points and lysates were subjected to western 
blotting using the indicated antibodies. GAPDH protein levels were determined as a 
loading control. The Myc bands in the western blot image were quantified using 
ImageJ, normalized to the GAPDH bands and are presented as fold change relative to 
D0 levels. Error bars represent standard deviation (n=3). (B)  Flow cytometric 
analysis of terminal erythroid maturation. At 48 hours post infection, Control, Myc-
GFPlow and Myc-GFPhigh cells were analyzed by flow cytometry. Erythroid 
differentiation was assayed by quantifying the CD71+TER119+ population, which 
represents the late stage erythroid cells (top). Enucleation was assayed by quantifying 
the TER119+Hoechst- populations, which correspond to the enucleated reticulocytes 
(middle). Apoptosis and cell death were assessed by co-staining with Annexin V and 
propidium iodide (bottom). 
 
 
3.3. Ectopic Myc expression at supraphysiological levels inhibits the 
expression of key erythroid transcripts and hemoglobin 
To confirm the inhibition of terminal erythroid differentiation by over-
expression of Myc at supraphysiological levels, the expression levels of key 
erythroid genes that are normally upregulated during terminal erythroid 
maturation were examined. We used quantitative real-time polymerase chain 
reaction (qRT-PCR) to compare the expression of key erythroid transcripts in 
Myc-GFPlow, Myc-GFPhigh and control cells. The transcript levels of 
hemoglobin isoforms (Hbb-b1, Hbb-b2 and Hba-a1), an erythroid-specific 
membrane protein (Spectrin α-chain) and an erythroid-specific cell surface 
protein (Glycophorin A) were normal in Myc-GFPlow cells but significantly 
lower in Myc-GFPhigh cells (Figure 3A). We next compared the hemoglobin 
content of these cells by Drabkins assay. The hemoglobin content of Myc-
GFPhigh cells was also significantly lower than that of control, whereas the 
hemoglobin level of Myc-GFPlow cells was comparable to that of the control 
cells (Figure 3B). 
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Figure 3. Ectopic Myc expression at supraphysiological levels inhibits erythroid 
differentiation. TER119-negative fetal liver erythroblasts were infected with 
bicistronic retroviruses encoding GFP only as control, or both Myc and GFP at 0 
hours in culture. At 24 hours post infection, cells were sorted based on GFP intensity 
into low (Myc-GFPlow) and high (Myc-GFPhigh) intensity populations, and then 
cultured for another 24 hours to allow for differentiation. (A) Cells were harvested at 
48 hours post-infection, and qRT-PCR analysis was performed to measure relative 
mRNA levels of the indicated genes. (B) Relative hemoglobin content was quantified 
at 48 hours post-infection, by cell lysis in Drabkin’s reagent followed by 
measurement of absorbance at 540 nm. Error bars represent standard deviation (n=3). 
Two-tailed t-test are indicated by (**) p<0.01. 
 
3.4. Myc expression at supraphysiological levels prevents exit from the 
cell cycle 
Since Myc overexpression is known to drive cell proliferation, we tested the 
effect of ectopic Myc expression at physiological and supraphysiological 
levels on terminal proliferation and the exit from the cell cycle. Total cell 
counts were measured at 48 hours in culture, relative to an equal number of 
sorted cells at 24 hours, to evaluate the effect of ectopic Myc on terminal 
proliferation (Figure 4A). We normalized the absolute cell numbers to account 
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for enucleation, where one erythroblast forms a nucleus and a reticulocyte, and 
demonstrated that continued Myc expression at physiological levels had no 
effect on terminal proliferation. The absolute cell counts for Myc-GFPhigh 
cells at 48 hours were significantly lower than that of control (Figure 4A), and 
this reduction was explained by the significant induction of apoptosis by 
supraphysiological levels of Myc (Figure 2B). We next performed cell cycle 
analysis at 48 hours in culture to investigate the effect of ectopic Myc 
expression on the erythroid cell cycle exit. Myc-GFPlow cells accumulated in 
the G1 phase of the cell cycle similar to the control cells. In contrast, Myc-
GFPhigh cells showed a significant population of cells in the S-phase 
indicating that the cells were continuing to cycle (Figure 4B). 
 
      
Figure 4. Ectopic Myc expression at supraphysiological levels prevents exit from 
the cell cycle. (A) Cell counts measured at 48 hours post-infection, for an equal 
starting cell number (25x104) at 24 hours after sorting based on GFP intensity. The 
total cell numbers are represented as black bars. The numbers were normalized to 
account for enucleation using the equation N = total cell number x (1-percentage 
enucleation/100) and are shown as white bars. Error bars represent standard deviation 
(n=3). Two-tailed t-test are indicated by (**) p<0.01. (B) Cell cycle analysis by flow 
cytometry at 48 hours post-retroviral infection.  
 
 38 
In summary, continued expression of Myc at a physiological range does not 
affect the terminal erythroid differentiation, terminal proliferation or exit from 
the cell cycle, but specifically blocks erythroid enucleation. However, 
overexpression of Myc at levels above the physiological range in the erythroid 
cells blocks terminal differentiation, promotes continued proliferation and 
induces significant levels of apoptosis.  
 
3.5. Myc-GFPhigh cells continue to proliferate in culture in special 
growth factor-free conditions 
The Myc-GFPhigh cells continued to proliferate even in erythropoietin-free 
culture conditions (in DMEM containing 10% serum and antibiotics) for at 
least 8 weeks. Since the ability to grow in special growth factor-free culture 
conditions is associated with transformed cells, we next tested these cells for 
potential for erythroleukemia generation. Myc-GFPhigh erythroblasts (at least 
105 cells/mouse, in 250 μl PBS) were transplanted retro-orbitally into sub-
lethally irradiated (6 Gy) C57/BL6 mice, and were monitored for their 
complete blood counts periodically (Table 4). None of the transplanted mice 
showed evidence of erythroleukemia development even after 6 months post-
transplant, suggesting that Myc alone was not sufficient to fully transform 
erythroblasts into erythroleukemia initiating cells. This is consistent with the 
conclusions from a previous study129, where retroviral overexpression of Myc 
in mice fetal liver cells gave rise to continuously growing erythroblast cell 
lines but did not fully transform them. These results indicate that Myc 
overexpression at supraphysiological levels in early erythroblasts promotes 
proliferation at the expense of differentiation without tranforming them.      
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Table 4. Complete blood counts for mice transplanted with Myc 
overexpressing erythroblasts. Complete blood cell counts for the mice 
transplanted with freshly sorted (971–976) or cultured (948-954) Myc-GFPhigh cells 
were monitored using an automatic hematology analyzer (Celltac alpha MEK-6358, 
Nihon Kohden, Tokyo, Japan). Mouse no. 971 died at 5 months without evidence of 
erythroleukemia. WBC, RBC and PLT represent the white blood cell, red blood cell 
and platelet counts. HCT represents the hematocrit. MCV represents mean 
corpuscular volume, which is an indication of the average size of the red blood cells. 
MCH represents mean corpuscular hemoglobin, indicating the amount of hemoglobin 
per red blood cell. MCHC is the mean corpuscular hemoglobin concentration, which 
is an indication of amount of hemoglobin relative to the size of the red blood cell.  
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3.6. Overexpression of Cyclin D1 does not affect terminal erythroid 
differentiation or exit from the cell cycle 
Myc overexpression at supraphysiological levels blocked terminal erythroid 
differentiation and overcame the cell cycle arrest in the G1-phase observed 
during normal erythroid maturation. This prompted us to test whether 
overexpression of other positive regulators of G1-S transition such as Cyclin 
D1130,131 can mimic the effect of ectopic Myc expression on terminal erythroid 
maturation. Cyclin D1 also has CDK-independent functions as a cofactor for 
several transcription factors132, making it an attractive candidate to imitate the 
effect of Myc overexpression. Cyclin D1 and Myc transcripts have been 
reported to be transiently downregulated during the bcr-abl tyrosine kinase 
inhibitor STI571-induced erythroid differentiation of K562 human 
erythroleukemia cell line133. This study reported that ectopic cyclin D1 
expression blocked the STI571-induced erythroid differentiation of K562 cells. 
We cloned the cyclin D1 gene into the MSCV-IRES-GFP retroviral vector in 
order to test the effect of cyclin D1 overexpression on terminal maturation of 
primary mouse fetal liver erythroblasts. As a first step, we monitored the 
changes in cyclin D1 transcript levels during in vitro differentiation of purified 
TER119-negative mouse fetal erythroblasts (Figure 5A).  The levels of cyclin 
D1 expression was significantly reduced at 24 (D1) and 48 hours (D2) in 
culture, relative to the expression levels in freshly purified erythroblasts (D0). 
We next infected the purified TER119-negative erythroblasts with retroviruses 
encoding both Cyclin D1 and GFP, or as controls retroviruses encoding GFP 
alone, followed by culture in erythropoietin-containing medium. At 48 hours 
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post-infection, the enucleation and differentiation was quantified by flow 
cytometry (Figure 5B). 
          
Figure 5. Terminal erythroid differentiation and enucleation is unaffected by 
overexpression of cyclin D1. (A) qRT-PCR analysis of cyclin D1 expression levels 
in erythroblasts harvested at 0 (D0), 24 (D1) and 48 hours (D2) in culture. (B) 
TER119-negative fetal liver erythroblasts were infected with bicistronic retroviruses 
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encoding GFP only as control, or both cyclin D1 and GFP at 0 hours in culture. 
Differentiation (top), enucleation (middle), and apoptosis (bottom) were quantified by 
flow cytometry at 48 hours in culture. (C) Cell cycle analysis of cells harvested at 48 
hours in culture by flow cytometry (D) Cell counts measured at 48 hours in culture, 
for an equal starting cell number (106). The total cell numbers are represented as 
black bars. The numbers were normalized to account for enucleation, and are shown 
as white bars. (E) qRT-PCR analysis of cyclin D1 expression levels at 48 hours in 
culture, in cells infected with retroviruses encoding cyclin D1 relative to control cells 




The cyclin D1 overexpressing cells did not show any significant changes in 
enucleation or terminal differentiation compared to control cells (Figure 5B). 
Ectopic cyclin D1 was unable to overcome the exit from cell cycle during late 
stage erythroid maturation (Figure 5C), and also did not have any apparent 
effect on terminal proliferation of cultured erythroid cells (Figure 5D). qRT-
PCR analysis of cyclin D1 transcript levels indicated that erythroblasts 
infected with cyclin D1-encoding retroviruses expressed the cyclin D1 
transcript at about 3000-fold higher than control cells (Figure 5E). This 
demonstrated that overexpression of cyclin D1 at levels much higher than 
physiological levels failed to disrupt normal terminal erythroid maturation, 
enucleation and cell cycle arrest. Our findings contradict the conclusions of 
the study using K562 erythroleukemia cells where cyclin D1 overexpression 
blocked terminal erythroid differentiation induced by STI571, possibly due to 
the result of the different cell systems used as models of terminal erythroid 
differentiation. We believe that our observations in normal, primary mouse 
fetal erythroblasts are more physiologically relevant compared to observations 
in transformed cell lines. The inability of ectopic cyclin D1 to perturb normal 
terminal erythroid maturation and proliferation provides an indirect evidence 
for the specificity of Myc function in regulating these changes during terminal 
erythroid differentiation. 
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3.7. Inhibition of Myc function by shRNA or small molecule inhibitors 
inhibits terminal proliferation without affecting terminal differentiation 
Since ectopic Myc expression had significant effects on terminal erythroid 
differentiation depending on the dose of Myc, we next performed loss-of-
function studies using Myc shRNA and a small molecule inhibitor of Myc 
function. Myc is downregulated progressively during terminal erythroid 
maturation, indicating that downregulation of Myc may regulate the exit from 
the cell cycle. We wanted to test whether acceleration of the loss of Myc 
function during terminal erythroid maturation affects terminal proliferation 
and the exit from the cell cycle. 
 
 In order to test the role of Myc in regulating the rapid terminal proliferation of 
erythroid cells, we infected purified TER119-negative erythroblasts with 
retroviruses harboring shRNA against Myc or with retroviruses encoding non-
silencing negative control shRNA, followed by culture for 48 hours in 
erythropoietin-containing medium. There was no significant effect of 
knockdown of Myc on erythroid differentiation, enucleation or apoptosis 
(Figure 6A), but proliferation was significantly reduced in cells expressing 
Myc shRNA (Figure 6B). Western blot analysis confirmed the reduction of 
Myc protein levels in cells expressing Myc shRNA, and the upregulation of 
p27 was unaffected by knockdown of Myc (Figure 6C). Accelerated depletion 
of Myc significantly reduced the proliferation of differentiating erythroid cells, 
suggesting that Myc levels may regulate the number of cell divisions during 





Figure 6. Depletion of Myc by shRNA inhibits terminal proliferation of 
erythroblasts without affecting terminal differentiation (A) Purified TER119-
negative erythroblasts were infected with retroviruses encoding shRNA against Myc, 
or control retroviruses encoding non-silencing negative control shRNA, followed by 
culture in erythropoietin containing medium. The cells were analyzed by flow 
cytometry after 48 hours in culture. Erythroid differentiation was assayed by 
quantifying the CD71+TER119+ population, which represents the late stage erythroid 
cells (left). Enucleation was assayed by quantifying the TER119+Hoechst- 
populations, which corresponds to the enucleated reticulocytes (middle). Apoptosis 
and cell death were assessed by co-staining with Annexin V and propidium iodide 
(right).  (B) Cell counts were measured at 48 hours in culture for the same cells as in 
panel A, for an equal starting cell number (50x104). The total cell numbers are 
represented as black bars. The numbers were normalized to account for enucleation 
using the equation N = total cell number x (1-percentage enucleation/100) and are 
shown as white bars. Error bars represent standard deviation (n=3). Two-tailed t-test 
are indicated by (**) p<0.01 (C) Western blot analysis of the same cells as in Panel A, 






In order to further confirm the observations from the Myc shRNA experiments, 
we used small molecule Myc inhibitor 10058-F4134, which inhibits the 
interaction of Myc with its transcriptional partner Max, and prevents the 
transcription of Myc target genes since Myc-Max interaction is necessary for 
Myc to activate transcription of its targets. The working concentration of this 
inhibitor is 64 μM. We studied a dose-response of this inhibitor on erythroid 
terminal proliferation and differentiation (Figure 7).  
 
 The FACS data shows that increasing doses of Myc inhibitor, even well 
beyond its standard working concentration, does not have any significant 
effect on terminal differentiation and enucleation of the in vitro cultured fetal 
erythroblasts (Figure 7A). There was also no effect of the various 
concentrations of the drug on the apoptosis levels in these cultures (Figure 7A). 
Since Myc levels decrease during the course of normal terminal erythroid 
differentiation, it is not surprising that inhibition of Myc function did not have 
a significant effect on the differentiation program in these cells. The only 
dose-dependent effect of the Myc inhibitor on these cells was a decrease in 
proliferation as the inhibitor concentration increased (Figure 7B). This is 
consistent with our observations from the experiments involving Myc shRNA 
(Figure 6). In conclusion, shRNA-mediated depletion of Myc or suppression 
of Myc function by small molecule inhibitors in cultured erythroblasts 
significantly inhibited terminal cell proliferation without affecting terminal 
differentiation. These results indicate that a precisely regulated decrease in 
Myc levels during late stage erythroid maturation may control the exact 




Figure 7. Small molecule Myc inhibitor affects proliferation without affecting 
other aspects of terminal erythroid differentiation.  C-myc inhibitor (10058-F4) 
was added at different doses (as indicated) to the purified E13.5 fetal liver 
erythroblasts at zero hour and cultured for 2 days in fibronectin coated plates and 
erythropoietin containing medium. DMSO (vehicle control) was used in the 0 μM 
treatment. (A) At different doses of myc inhibitor, the terminal differentiation, 
enucleation and apoptosis of the erythroblasts were analyzed by flow cytometry at 48 
hours in culture. (B) Total cell counts were measured for an equal starting cell 







3.8. p27 is dispensable for terminal erythroid differentiation and cell cycle 
arrest 
Myc overexpression at supraphysiological levels in erythroid cells prevented 
their withdrawal from the cell cycle (Figure 4B), and diminished the induction 
of p27 during late stage erythroid maturation (Figure 2A, lanes 7 and 9). p27 
has been implicated in the cell cycle arrest during the final stages of erythroid 
maturation11. This prompted us to investigate whether p27 protein levels were 
the critical mediators of cell cycle arrest during terminal erythroid 
differentiation and whether the effect of Myc on cell cycle in erythroid cells 
was mediated through its regulation of p27 protein levels.  
 
To this end, we purified TER119-negative fetal liver erythroblasts from E13.5 
transgenic embryos that were wild-type (p27+/+), heterozygous (p27+/-) or 
nullizygous (p27-/-) for the p27 locus, and compared their terminal 
differentiation in vitro to test if p27 was necessary for normal terminal 
erythroid maturation and cell cycle arrest. Differentiation, enucleation and 
apoptosis were quantified by flow cytometry at 48 hours of culture, and no 
significant difference was observed between the p27+/+, p27+/- and p27-/- cells 
(Figure 8A). There was also no significant difference in the extent of G1-arrest 
(Figure 8B) and terminal proliferation (Figure 8C) in the absence of one or 
both alleles of p27. Western blot analysis was performed to confirm the 
complete absence of p27 protein in the p27-/- erythroblasts at 48 hours in 
culture (Figure 8D), and the protein levels were intermediate in p27+/- cells 
consistent with previous studies13-15. These results demonstrate that terminal 
erythroid differentiation and cell cycle arrest occurred normally even in the 
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absence of p27, and suggest that the effect of Myc overexpression on cell 
cycle progression in erythroid cells may not be mediated by p27 alone.  
 
The adult p27 knockout mice are larger in body size than their wild-type 
counterparts, but there are no apparent defects in the proportions of various 
cell types in peripheral blood15. The p27 knockout mice have increased 
number of BFU-Es and CFU-Es in the spleen and bone marrow15. This 
suggests that the increased blood production for the larger body size in p27 
knockout mice may be a result of increased production of early progenitors 
such as BFU-E and CFU-E, though the terminal erythroid maturation and 
number of terminal cell divisions starting from the CFU-E stage remain 
normal.  
 
The p27 protein is strongly induced during late stages of erythroid maturation, 
coinciding with the withdrawal from the cell cycle. Here we demonstrate that 
terminal differentiation and exit from cell cycle is normal even in complete 
absence of p27. This raises the possibility that induction of p27 may be a 
consequence, and not the cause, of cell cycle arrest induced by downregulation 
of Myc in late stage erythroid cells.  This is consistent with the direct 
repression of p27 transcription by Myc71 binding. Downregulation of Myc 
during late stages of erythroid maturation relieves the transcription repression 
of p27, leading to the strong induction of p27 mRNA and protein. Though p27 
may play important roles in mechanistically affecting the cell cycle arrest in 
late stage erythroblasts, our results from p27 knockout studies demonstrate 
that p27 is dispensable for normal terminal erythropoiesis. 
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Figure 8. Terminal erythroid differentiation is not affected by deficiency of p27. 
TER119-negative fetal liver erythroblasts were purified from p27+/+, p27+/- and p27-/- 
E13.5 mouse embryos and cultured in erythropoietin-containing medium in 
fibronectin-coated plates for 48 hours. (A) Differentiation (top), enucleation (middle), 
and apoptosis (bottom) were quantified by flow cytometry at 48 hours in culture, as 
described in Figure 1B. (B) Cell cycle analysis of cells harvested at 48 hours in 
culture by flow cytometry (C) Cell counts measured at 48 hours in culture, for an 
equal starting cell number (1 x 105). The total cell numbers are represented as black 
bars. The numbers were normalized to account for enucleation as in Figure 3, and are 
shown as white bars. All error bars represent standard deviation (n=3). (D) Western 
blot analysis to determine p27 protein levels. GAPDH protein levels were determined 
as a loading control. 
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3.9. Ectopic Myc expression inhibits nuclear condensation in late stage 
erythroid cells 
To further characterize the block in the ability of the Myc-expressing cells to 
undergo enucleation, we performed benzidine-Giemsa staining to study cell 
morphology (Figure 9A). The Myc-GFPhigh cells did not stain strongly with 
benzidine showing a lack of hemoglobinization, and were similar in 
appearance to early erythroblasts- large cells with large nuclei. This further 
confirmed that Myc expression at supraphysiological levels arrested terminal 
differentiation in an early erythroblast stage. There was no apparent difference 
in benzidine staining between Myc-GFPlow cells and control cells at 48 hours 
in culture, confirming that ectopic Myc expression at physiological levels had 
no effect on erythroid maturation and hemoglobinization (Figure 9A). 
Importantly, the nuclei in the late-stage Myc-GFPlow erythroblasts were 
larger and more centralized compared to the control cells at 48 hours in culture, 
but were smaller than the nuclei of erythroblasts in earlier stages of 
development harvested at 0 hours and 24 hours in culture (Figure 9A). To 
confirm this observation, we used Cellomics high content screening (HCS) to 
measure and compare the erythroid nuclear size in a quantitative manner. The 
nuclear area per cell was significantly higher for Myc-GFPlow cells compared 
to control cells at 48 hours in culture, and both values were significantly lower 
than those of erythroblasts in earlier stages of development harvested at 0 
hours and 24 hours in culture (Figure 9B). These results demonstrate that 
ectopic Myc expression inhibits nuclear condensation in late stage erythroid 
cells, and suggest that the observed block in enucleation due to Myc 
expression was a result of inhibition of nuclear condensation.  
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Figure 9. Downregulation of Myc is essential for erythroid nuclear condensation. 
Purified TER119-negative mouse fetal erythroblasts were infected with retroviruses 
encoding GFP only (MIG), or with retroviruses encoding both Myc and GFP at 0 
hours in culture and sorted based on GFP intensity into low (Myc-GFPlow) and high 
(Myc-GFPhigh) intensity populations at 24 hours post infection, followed by culture 
for another 24 hours to allow for differentiation in-vitro (A) At 48 hours post-
infection, the MIG control, Myc-GFPlow, and Myc-GFPhigh cells were cytospun 
onto glass slides and stained with benzidine and Giemsa. Cytospin preparations of 
uninfected erythroblasts harvested at 0 hours (D0) and 24 hours (D1) in culture were 
also stained with benzidine and Giemsa as earlier time-point controls for comparison. 
Arrowhead indicates an enucleated reticulocyte. Arrows indicate erythroblasts with 
condensed nuclei that are in an early stage of enucleation. (B) Measurement of 
nuclear area to quantify the degree of nuclear condensation. Cells were harvested as 
described in panel A, fixed with formaldehyde, and incubated with Hoechst 33342 to 
stain the nucleus. Nuclear area per cell was determined for each sample using high 
content screening, as described in methods section. Error bars represent standard 






3.10. Downregulation of Myc is essential for global histone deacetylation 
during late stages of erythroid maturation 
We next investigated the molecular mechanism underlying the inhibition of 
nuclear condensation and enucleation by Myc. Pharmacological inhibition of 
histone deacetylases (HDACs) has been reported to block chromatin 
condensation and enucleation in erythroid cells127, suggesting a role for global 
histone acetylation in regulating chromatin condensation. Recent studies have 
shown that Myc regulates global chromatin structure by influencing 
widespread histone modifications135-137. We thus sought to determine if Myc 
expression induces changes in global histone acetylation in erythroid cells, 
possibly leading to the observed block in chromatin condensation.  
 
To this end, we performed Western blot analysis of histone acetylation using 
antibodies detecting histones H3 and H4 acetylated at specific lysine residues 
(Figure 10).  Global levels of acetylation of histone H3 at K9 was maximal at 
24 hours in culture and decreased slightly at 48 hours in culture. Ectopic Myc 
expression reversed the observed decrease in acetylation at H3K9 during late 
stage erythroid maturation. There was no change in levels of H3K18 and 
H3K23 acetylation during the course of erythroid maturation with or without 
ectopic Myc expression. Global levels of histone H4 acetylation at K5, K8, 
K12 and K16 decreased at 48 hours in culture concomitant with the nuclear 
condensation observed during late stage erythroid maturation, and were 
rescued by ectopic Myc expression at both physiological and 
supraphysiological levels. Hence continued Myc expression even at a 
physiological level blocked the global decrease in histone acetylation observed 
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during late stage erythroid maturation, suggesting that histone deacetylation 
mediated by downregulation of Myc during terminal erythroid differentiation 
is important for nuclear condensation and enucleation.  
                             
Figure 10. Downregulation of Myc is essential for global histone deacetylation 
during late stages of erythroid maturation. Cells were treated and harvested as 
described in Figure 9, and Western blot analysis of acetylation states of histones H3 
and H4 was performed using the indicated acetylation-specific antibodies. Equal 
loading of samples was confirmed by stripping and reprobing the membranes with 
total histone H3 or H4 antibodies. 
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3.11. Changes in expression of HATs and HDACs upon ectopic Myc 
expression at physiological levels 
Since changes in global histone acetylation accompanied the block in 
erythroid nuclear condensation in Myc-GFPlow cells, we investigated the 
changes in expression of the major histone acetyltranferases (HATs) and 
histone deacetylases (HDACs) as a result of Myc expression at physiological 
levels (Figure 11). The HAT Gcn5 was upregulated by 2-fold upon Myc 
expression, while the expression of other HATs and HDACs did not change 
significantly. This result suggested that Myc expression countered the histone 
deacetylation observed during late stage erythroid maturation by upregulation 
of the Gcn5 HAT activity, leading us to investigate the role of Gcn5 in 
terminal erythroid maturation. 
 
 
Figure 11. qRT-PCR analysis showing the effect of continued myc expression at 
physiological levels on the expression of Histone acetyltransferases (HATs) and 
Histone deacetylases (HDACs) in erythroid cells differentiating in vitro.  
TER119-negative mouse fetal erythroblasts were infected with bicistronic 
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retroviruses encoding both GFP and Myc, or GFP alone as control followed by 
culture in erythropoietin containing medium for 24 hours. Myc-GFPlow cells were 
sorted at 24 hours post-infection by gating on the low GFP intensity populations, and 
GFP-positive cells in the control populations were sorted as controls. The cells were 
cultured for a further 24 hours to allow for differentiation. RNA was extracted at 48 
hours post-retroviral infection and qRT-PCR was performed to measure relative 
mRNA levels of the indicated HATs (Top) and HDACs (Bottom). All error bars 
represent standard deviation (n=3). Two-tailed t-test are indicated by (**) p<0.01. 
 
 
3.12. Ectopic Gcn5 expression inhibits erythroid enucleation 
To directly investigate the role of Gcn5 in terminal erythroid maturation and 
enucleation, we infected TER119-negative mouse fetal erythroblasts with 
retroviruses encoding Gcn5. The levels of Gcn5, Myc and p27 proteins in cells 
infected with retroviruses encoding Gcn5 were compared with the expression 
levels during normal erythroid maturation and also with Myc expressing cells 
using Western blot analysis (Figure 12A). Gcn5 protein levels decreased 
substantially during late stage erythroid maturation coinciding with the onset 
of nuclear condensation, similar to the decrease in Myc protein levels at the 
same stage (Figure 12A, lanes 1-3). Ectopic Myc expression increased the 
Gcn5 protein expression significantly (Figure 12A, lanes 3 and 4), consistent 
with the induction of Gcn5 transcripts by Myc (Figure 11). Cells infected with 
retroviruses encoding Gcn5 displayed elevated levels of Gcn5 protein 
expression relative to controls, but the levels of Myc and p27 were not 
affected (Figure 12A, lanes 3 and 5). Ectopic Gcn5 expression inhibited 
erythroid enucleation significantly without affecting differentiation or 
apoptotic status of the cultured erythroid cells (Figure 12B). The hemoglobin 
content of Gcn5 expressing cells was similar to those of the controls (Figure 
12C), further confirming that the inhibition of enucleation was not due to a 




Figure 12. Ectopic Gcn5 expression inhibits erythroid enucleation. (A) TER119-
negative mouse fetal erythroblasts were cultured for 0 hours (D0) and 24 hours (D1), 
or were cultured for 48 hours after infection with bicistronic retroviruses encoding 
GFP and Myc (D2 Myc), GFP and Gcn5 (D2 Gcn5) or GFP alone (D2 control). Total 
protein lysates from the cells were subjected to western blot analysis using the 
indicated antibodies. (B) TER119-negative mouse fetal erythroblasts were infected 
with bicistronic retroviruses encoding Gcn5 and GFP (Gcn5) or GFP alone (Control). 
The cells were analyzed by flow cytometry after 48 hours in culture to quantify 
enucleation (i), differentiation (ii) and apoptosis (iii). (C) Relative Hemoglobin 
content was quantified by lysing cells in Drabkin’s reagent followed by measurement 
of absorbance at 540 nm. Error bars represent standard deviation (n=3). 
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Gcn5 expression did not affect the terminal proliferation rates of 
differentiating erythroblasts (Figure 13A) or their withdrawal from cell cycle 
after 48 hours in culture (Figure 13B). Hence ectopic Gcn5 expression 
specifically inhibits erythroid enucleation without affecting the other aspects 
of terminal erythroid maturation program, indicating that downregulation of 
Gcn5 in late stage erythroid cells is necessary for normal erythroid enucleation. 
 
 




Figure 13. Ectopic Gcn5 expression does not affect proliferation or withdrawal 
from the cell cycle. (A) Cell counts were measured at 48 hours for an equal starting 
cell number (1x105) at 0 hours. The total cell numbers are represented as black bars. 
The number was normalized to account for enucleation and is shown as white bars. 
(B) The cells were harvested at 48 hours in culture and cell cycle analysis was 
performed by flow cytometry. The percentage of cells in G1, S and G2 phase of cell 






3.13 Ectopic Gcn5 expression inhibits nuclear condensation and histone 
deacetylation in late stage erythroid cells similar to ectopic Myc 
expression 
We next evaluated the effect of Gcn5 expression on nuclear condensation in 
late stage erythroid cells. Benzidine-Giemsa staining of Gcn5 expressing cells 
at 48 hours in culture indicated late stage erythroblasts with larger nuclei 
relative to controls, with no apparent difference in hemoglobin content (Figure 
14A). High content screening-based measurement of nuclear area confirmed 
that the average nuclear size of Gcn5-expressing erythroblasts was 
significantly higher than those of control cells at 48 hours in culture (Figure 
14B). Furthermore, Western blot analysis of global acetylation states of 
histones H3 and H4 demonstrated that Gcn5 expression significantly rescued 
the histone deacetylation at H3K9, H4K8 and H4K12 observed during late 
stage erythroid maturation, similar to the effects of ectopic Myc expression 
(Figure 14C). The acetylation states of H4K5, H3K18 and H3K23 remained 
unchanged, while H4K16 acetylation was slightly increased upon Gcn5 
expression. These results indicate that downregulation of Gcn5 in late stage 
erythroblasts is critical for the global histone deacetylation leading to erythroid 
nuclear condensation and enucleation. 
 
Since Gcn5 expression was induced by ectopic Myc expression in erythroid 
cells, and both were downregulated substantially and simultaneously in late 
stage erythroblasts (Figure 12A), we reasoned that Gcn5 could be a direct 
transcriptional target of Myc in erythroid cells. Gcn5 has been shown to be a 
direct Myc target gene in human fibroblasts137. Chromatin 
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immunoprecipitation (ChIP) assays were performed on purified TER119-
negative mouse fetal erythroblasts using an antibody against Myc. The 
immunoprecipitated DNA was significantly enriched for Gcn5 promoter 
sequences relative to negative control regions chosen 1500 bp away from the 
Gcn5 transcriptional start site (TSS) (Figure 14D). Taken together, these 
results indicate that Gcn5 is transcriptionally regulated by Myc in erythroid 
cells, and it functions downstream of Myc to regulate global histone 



























Figure 14. Ectopic Gcn5 expression inhibits nuclear condensation and histone 
deacetylation in late stage erythroid cells similar to ectopic Myc expression. (A) 
TER119-negative fetal erythroblasts were cultured for 48 hours after infection with 
bicistronic retroviruses encoding GFP and Gcn5 (Gcn5) or GFP alone (Control). The 
cells were cytospun onto glass slides and stained with benzidine and Giemsa. Scale 
bar represents 20 µm. (B) The same cells as in panel A were harvested at 48 hours in 
culture, fixed and stained with Hoechst 33342. Nuclear area per cell was measured by 
high content screening.  (C) TER119-negative fetal erythroblasts were cultured for 48 
hours after infection with retroviral vectors encoding GFP and Myc, GFP and Gcn5, 
or GFP alone as control. Histones were isolated by acid extraction and Western blot 
analysis of acetylation states of histones H3 (16 kD) and H4 (11 kD) was performed 
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using the indicated antibodies. (D) Chromatin immunoprecipitation (ChIP) assay 
showing Myc binding to the Gcn5 promoter. ChIP was performed on purified 
TER119-negative mouse fetal liver erythroblasts using an antibody against c-Myc. 
PCR primers were designed for prospective Myc binding regions in the Gcn5 
promoter at -3 to -96 and -44 to -142 bp upstream of the Gcn5 transcriptional start site 
(TSS). The enrichment for Gcn5 promoter sequences in the immunoprecipitated DNA 
was quantified using qRT-PCR, relative to a negative control region at -1596 to -1690 
bp upstream of the Gcn5 TSS. All error bars represent standard deviation (n=3). 
 
 
3.14 Screening for other histone acetyltransferases that regulate 
enucleation 
Ectopic Gcn5 expression in cultured erythroblasts led to a partial block in 
enucleation without affecting terminal differentiation and proliferation. This 
indicates that downregulation of Gcn5 during late stage erythroid maturation 
contributes to the decrease in global histone acetylation observed during late 
stages of terminal erythroid maturation. Since the enucleation block by Gcn5 
was only partial, we hypothesized that other HATs may also regulate the 
global histone acetylation states during late stage erythroid maturation. This 
led us to screen for other HATs that may play important roles in regulating 
erythroid enucleation. As a first step, we investigated the expression levels of 
the mRNA for various HATs during the course of terminal erythroid 
maturation (Figure 15). We measured the relative mRNA levels of 6 different 
HATs besides Gcn5, namely Elp3, Hat1, PCAF, Tip60, CBP and p300 in 
cultured erythroblasts at 0 (D0), 24 (D1) and 48 hours (D2) in culture using 
qRT-PCR. The expression levels of Elp3, Hat1, Tip60 and Gcn5 were 
significantly downregulated during the late stages of terminal erythroid 
maturation. The expression of CBP, PCAF and p300 did not decrease during 
the course of terminal erythroid maturation. This suggested that the observed 
decrease in global histone acetylation during late stage erythroid maturation 
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may be a result of decrease in the expression of individual HATs such as Gcn5, 
Elp3, Hat1 and Tip60. 





























Figure 15. qRT-PCR analysis of the expression of Histone acetyltransferases in 
erythroid cells differentiating in vitro.  TER119-negative mouse fetal erythroblasts 
were cultured in erythropoietin containing medium, and samples were taken at 0 (D0), 
24 (D1) and 48 (D2) hours in culture for qRT-PCR analysis. The mRNA expression 
for each HAT was normalized to D2. Error bars represent standard deviation (n=3). 
 
To test the role of downregulation of each of these individual HATs in 
erythroid enucleation, we cloned the open reading frames (ORFs) for Elp3, 
Hat1, PCAF and Tip60 into MSCV-IRES-GFP retroviral vector and 
performed overexpression studies in erythroid cells. Although CBP and p300 
were also cloned into retroviral vectors, the size of the ORFs (> 7kb) was too 
large for proper packaging of the retroviruses and hence no infection and 
overexpression in erythroid cells was obtained. Due to the limitation of the 
retroviral expression system which can package and deliver inserts only upto 
5Kb in an efficient manner, the gain-of-function studies for CBP and p300 
were not possible in our experimental system.  TER119-negative mouse fetal 
erythroblasts were infected with retrovirus encoding the HATs at 0 hours in 
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culture. GFP expression served as a reporter for infection and protein 
expression. The cells were harvested at 48 hours post infection and qRT-PCR 
was performed to evaluate the level of overexpression at the transcript level 
(Figure 16). The cells infected with retrovirus encoding GFP only were used 
as controls, and the fold change in expression was calculated relative to the 
controls.  

























Figure 16. qRT-PCR analysis of the levels of overexpression of various HATs.  
Purified TER119-negative mouse fetal erythroblasts were infected with retroviruses 
encoding the indicated histone acetyltransferases and cultured in erythropoietin 
containing medium for 48 hours, followed by RNA extraction for qRTPCR. Cells 
infected with retrovirus encoding GFP only served as controls for normalization to 
calculate the fold- overexpression. Error bars represent standard deviation (n=3). 
 
 
The retroviral vector based overexpression of the various HATs consistently 
resulted in high levels of overexpression of the corresponding HAT transgene 
(Figure 16). We next studied the effect of overexpression of these HATs on 
the terminal erythroid maturation and enucleation of cultured erythroblasts. 
Freshly purified TER119-negative erythroblasts were infected with 
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retroviruses encoding the various HATs followed by culture in erythropoietin-
containing medium for 48 hours post-infection. Cells infected with empty 
retroviruses encoding GFP only served as controls. The cells were harvested 
for FACS analysis to evaluate the enucleation and differentiation of the 
retrovirus-infected erythroblasts (Figure 17). 
 
A.  













































Figure 17. Effect of overexpression of various HATs on enucleation and 
differentiation of cultured erythroid cells.  Purified TER119-negative mouse fetal 
erythroblasts were infected with retroviruses encoding the indicated histone 
acetyltransferases and cultured in erythropoietin containing medium for 48 hours, 
followed flow cytometric analysis of enucleation (A) and differentiation(B). Cells 
infected with retrovirus encoding GFP only served as controls. Only live, GFP-
positive cells were gated for analysis of enucleation and differentiation. Error bars 
represent standard deviation (n=3). 
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The GFP-negative cells were gated out in order to rule out the uninfected cells 
from the analysis. Compared to the control cells, only Hat1 overexpressing 
cells showed a subtle decrease in enucleation efficiency (Figure 17A). The 
decrease in enucleation by overexpression of Hat1 was not statistically 
significant (two-tailed t-test p-value > 0.2). Overexpression of Elp3, PCAF 
and Tip60 also did not lead to a significant change in enucleation efficiency 
compared to the control cells. There was no reduction in the differentiation of 
cultured erythroblasts upon overexpression of any of the HATs (Figure 17B). 
Cell cycle analysis was performed to determine whether the overexpression of 
any of the HATs had an effect on the G1-phase cell cycle arrest at the end of 
48 hours in culture. None of the HATs tested affected the exit from cell cycle 
and accumulation in the G1-phase at the end of terminal erythroid 
differentiation in vitro (Figure 18A). Cell counts performed at 48 hours in 
culture for equal starting cell numbers indicated that overexpression of the 
various HATs did not have a significant effect on terminal proliferation of 
differentiating erythroid cells (Figure 18B). 
 
In summary, overexpression of the HATS Elp3, Hat1, PCAF and Tip60 did 
not have a significant effect on enucleation, terminal differentiation, terminal 
proliferation and cell cycle arrest of cultured mouse fetal liver erythroblasts. 
However, we cannot rule out the contribution of synergestic effects of these 
HATs in regulating enucleation in vivo. The significant downregulation of 
Elp3, HAT1 and Tip60 during late stages of erythroid maturation may, along 
with the decrease in Gcn5 levels, contribute to the shift in balance in favour of 





























Figure 18. Effect of overexpression of HATs on exit from the cell cycle and 
terminal proliferation.  (A) Cell cycle analysis by flow cytometry at 48 hours post-
retroviral infection. (B) Cell counts measured at 48 hours post-infection, for an equal 
starting cell number (5x105). The total cell numbers are represented as black bars. 
The numbers were normalized to account for enucleation using the equation N = total 
cell number x (1-percentage enucleation/100) and are shown as white bars. Error bars 
represent standard deviation (n=3).  
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3.15. Supraphysiological induction of Myc blocks differentiation at early 
stages of terminal erythroid maturation 
Myc-GFPhigh cells continue to proliferate in culture for several days in an 
undifferentiated state. To address the temporal effects of Myc induction in 
erythroid cells, we used a retroviral expression system to overexpress the 
fusion protein MycER138, where Myc activity can be switched on by addition 
of estrogen receptor agonist 4-hydroxytamoxifen (4-OHT). To this end, 
purified TER119-negative erythroblasts were infected with retroviruses 
encoding both MycER and GFP (MSCV-MycER-IRES-GFP) and cultured 
with and without addition of 4-OHT at the beginning of the culture. The extent 
of erythroid differentiation at various time points during the course of in vitro 
culture was assessed by measuring TER119-positive cells by flow cytometry 
(Figure 19A).  A significant block in differentiation by induction of MycER 
by 4-OHT became apparent during the later time points in culture; this lag 
may be attributed to the time taken for the expression of MycER protein after 
retroviral infection. Western blot analysis using a polyclonal anti-Myc 
antibody that recognized both MycER and endogenous Myc was used to 
compare the expression level of MycER with the endogenous Myc levels in 
control erythroblasts infected with retroviruses encoding only GFP.  MycER 
protein was expressed at levels above the endogenous Myc levels in purified 
erythroblasts at 0 hours in culture (Figure 19B). Hence induction of MycER 
with addition of 4-OHT at 0 hours in culture was functionally similar to 
overexpression of Myc at supraphysiological levels, and led to a block in 
terminal erythroid differentiation. We next added 4-OHT to MycER 
expressing cells at different time points during the course of in vitro culture, 
 68 
and flow cytometric analysis of differentiation, enucleation and apoptosis was 
performed at 48 hours in culture. The decrease in extent of erythroid 
differentiation (measured as the percentage of TER119-positive cells at 48 
hours in culture) was more dramatic when MycER was induced by 4-OHT 
addition at earlier time points in culture, showing that Myc blocked 
differentiation in the early stages of terminal erythroid maturation (Figure 19C, 
Top panel). A dramatic block in enucleation was observed in MycER 
expressing cells upon 4-OHT addition at any time during the course of the in 
vitro culture (Figure 19C, Middle panel). A significant block in enucleation 
was also observed in uninduced MycER expressing cells to which no 4-OHT 
was added, but the differentiation of these cells were similar to that of the 
MIG control. This effect is most likely due to the reportedly leaky nature of 
MycER system, where the MycER protein is slightly active even in the 
absence of 4-OHT especially when expressed at high levels139. This is 
consistent with our observation that ectopic Myc expression at low levels, 
within a physiological range, blocked enucleation specifically without 
affecting other aspects of terminal erythroid maturation. The earlier 4-OHT 
was added to MycER expressing cells, the higher the percentage of the 
apoptotic cells in culture at 48 hours (Figure 19C, Lower panel). This suggests 
that early erythroblasts are more susceptible to Myc-induced apoptosis than 
late stage erythroid cells that express high levels of the anti-apoptotic protein 
Bcl-XL (Bcl2l1)7. Alternatively, decrease in the time period of exposure of the 
cells to induced Myc activity may result in the corresponding decrease in 
apoptosis. In conclusion, the inducible MycER studies reaffirm our 
conclusions from our constitutive Myc overexpression studies. 
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Figure 19. Induction of Myc blocks differentiation in early stages of terminal 
erythroid maturation. (A) TER119-negative mouse fetal erythroblasts were infected 
with a bicistronic retrovirus encoding MycER and GFP. At 0 hours in culture, 1 μM 
4-hydroxytamoxifen (4-OHT) was added for induction of MycER or vehicle (ethanol) 
was added as control. The differentiation of induced (black bars) and uninduced cells 
(white bars) were quantified at different time points in culture by measuring the 
percentage of TER119-positive cells using flow cytometry. (B) Western blot showing 
the levels of MycER and endogeneous Myc levels in MycER expressing cells induced 
with 4OHT at 0 hours in culture, relative to endogenous Myc levels in control cells at 
0 hours and 48 hours in culture. (C) TER119-negative mouse fetal erythroblasts were 
infected with bicistronic retroviruses encoding MycER and GFP (MycER) or GFP 
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alone (MIG Control) and cultured in erythropoietin-containing medium for 48 hours. 
4-OHT was added at different time points as indicated. After 48 hours, cells were 
analyzed by flow cytometry for differentiation, enucleation and apoptosis, as 
described in Figure 1B. All error bars represent standard deviation (n=3). Two-tailed 
t-test are indicated by (*) p<0.05 or (**) p<0.01. 
 
3.16. Gene expression analysis demonstrates that Myc-GFPhigh cells are 
similar to early erythroblasts and Myc-GFPlow cells resemble late stage 
erythroid cells 
Since Myc is a pleiotropic transcription factor regulating several diverse 
cellular functions51,56, we next investigated the genes and pathways perturbed 
by ectopic Myc expression at physiological and supraphysiological levels in 
erythroid cells using microarrays. Total RNA was extracted from Myc-
GFPlow and Myc-GFPhigh cells at 48 hours in culture post retroviral infection, 
and from uninfected erythroblasts in culture at 0 (D0 WT), 24 (D1 WT) and 
48 hours (D2 WT) as controls. RNA was then processed for hybridization to 
Illumina microarrays. A hierarchical clustering analysis of the 2795 
differentially expressed genes was performed with the results shown in Figure 
20. Each sample contained 3 biological replicates (termed 1, 2 and 3) that 
correlated well with each other. Cluster analysis showed that the mRNA 
expression pattern of Myc-GFPhigh cells at 48 hours in culture was most 
similar to that of uncultured TER119-negative erythroblasts (D0 WT). The 
expression pattern of wild- type cells changed markedly during differentiation, 
comparing erythroblasts cultured for 48 hours (D2 WT) against uncultured 
TER119-negative erythroblasts (D0 WT). Importantly, the expression pattern 
of Myc-GFPlow cells at 48 hours in culture was most similar to that of 
differentiated erythroblasts (D2 WT) (Figure 20).  
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Figure 20. Microarray analysis demonstrates that global gene expression of 
Myc-GFPhigh cells is similar to early erythroblasts and Myc-GFPlow cells 
resemble differentiated late stage erythroid cells. (A)  TER119-negative fetal liver 
erythroblasts were purified from E13.5 mouse embryos and cultured in erythropoietin 
containing medium on fibronectin-coated plates. The cells were harvested at 0 hours 
(D0), 24 hours (D1) or 48 hours (D2) culture, or infected with bicistronic retroviruses 
encoding Myc and GFP at 0 hours in culture, and sorted based on GFP fluorescence 
into low (Myc-GFPlow) and high (Myc-GFPhigh) expression populations at 24 hours 
post infection, followed by culturing for another 24 hours. Total RNA was extracted 
from 3 biological replicates under each condition and processed for hybridization on 
Illumina microarrays. Hierarchical clustering of all treatments and replicates was 
performed on Beadstudio software using Pearson correlation with nesting by average 
linkage method. Numerical scale shows the 1-r distance metric where shorter 
branches denote greater similarity. Heatmap shows 2795 differentially expressed 
genes that are upregulated (red) or downregulated (green) by at least 2-fold in at least 
1 condition compared to the average of the D0 WT replicate controls. Color scale bar 
indicates relative fold change in gene expression compared to the average of D0 WT 
replicate controls on a Log2 scale.  
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The genes that are upregulated, unchanged or downregulated significantly in 
differentiated erythroblasts (D2 WT) relative to early erythroblasts (D0 WT) 
and are significantly perturbed upon ectopic Myc expression are denoted as 
gene subsets i, ii, and iii, respectively (Figure 20). 
 
 Gene subset i includes genes that are normally upregulated during erythroid 
differentiation. The significantly enriched gene ontology categories for each of 
these genes were identified using Ingenuity Pathway Analysis software 
(Figure 21 and Table 5).   
 
             
 
Figure 21.  The top significantly enriched gene ontology categories in the genes 
upregulated during normal terminal erythroid maturation but unchanged in 




The upregulation of this group of genes, which includes several erythroid 
important genes, is blocked in Myc-GFPhigh cells, consistent with the 
observed differentiation block in these cells. A significant number of these 
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genes was also perturbed in Myc-GFPlow cells suggesting that differentiation 
is not completely normal in these cells, although hemoglobin levels, TER119 
expression, and mRNA levels of the major red cell proteins were normal 
(Figures 2 and 3). The most obvious abnormality detected in these cells was a 
block in nuclear condensation and enucleation.  
 
The genes that are upregulated by at least 2-fold during normal erythroid 
maturation but not in Myc-GFPhigh cells include molecular and cellular 
functions such as cell growth and proliferation, cell death, cell cycle, cellular 
development, molecular transport, protein trafficking, cellular movement and 
cell morphology (Table 5). The upregulation of transcripts for the anti-
apoptotic protein Bcl-XL7 and the cyclin-dependant kinase inhibitors p21 and 
p2711 was normal in Myc-GFPlow cells, but were blocked in Myc-GFPhigh 
cells. The high levels of Bcl-XL in Myc-GFPlow cells, similar to the levels 
seen in normal late stage erythroblasts (D2 WT), may play an important role in 
avoiding Myc-induced apoptosis in the Myc-GFPlow cells. On the other hand, 
the upregulation of Bcl-XL is blocked in Myc-GFPhigh cells, which as a result 
show a significant apoptotic response. The lack of upregulation of p21 and 
p27 in Myc-GFPhigh cells is consistent with our observation that Myc-
GFPhigh cells continue to proliferate in culture for long periods with an early 
erythroblast morphology. Hence overexpression of Myc at supraphysiological 
levels blocks the upregulation of several erythroid important transcripts, 




Table 5. Genes upregulated in D2 WT cells but unaffected in Myc-GFPhigh cells 










 MBP, TCIRG1, BCL6, CTSS, OSM, CD274, MXI1, STK17B, 
MED7, TP53INP1, BTG1, SH3BP2, BMX, STX2, FYB, WWP2, 
HDAC5, TLR2, BCL2L1, CSF2RB, CD9, NDFIP1, DOK1, 
PRDX2, B2M, OSR2, CD55, CD74, JAK2, LOC643751, EP300, 
CDC25B, SLFN1, IGF1, ANXA1, STAT1, TNFRSF10A, HGS, 
IL4, APOBEC1, COL4A3BP, MDM2, STK3, MSI2, CSF1R, 
XPA, ISG15, LY6A, LY96, CAPNS1, GRAP2, KLF5, CDKN1A, 
BNIP3L, CDKN1B, PAFAH1B1, PRKCB 
 Cell Death 
 DYRK1B, AHSP, PDPK1, BCL6, TNIP1, UBE2B, CTSS, 
PPP1R13B, OSM, CD274, GPX4, STK17B, MED7, SHISA5, 
TP53INP1, DNASE2, DDIT4, ASAH1, WWP2, TLR2, BCL2L1, 
CD9, STRADB, USE1, ALDOA, HIST1H1C, USP18, ZFP36, 
JAK2, EP300, CDC25B, IGF1, AKT3, MAP1LC3B, STAT1, 
TNFRSF10A, IL4, MDM2, STK3, AXL, SOAT1, NFE2L1, XPA, 
LY6A, ROCK1, PGLYRP1, ATP6AP2, GNAS, LAMP2, 
CAPNS1, GRAP2, CDKN1A, KLF5, BNIP3L, CDKN1B, 
PAFAH1B1, PRKCB 
 Cell Cycle 
 JAK2, BCL6, LOC643751, EP300, CDC25B, SLFN1, IGF1, 
ANXA1, DSTN, OSM, CD274, STAT1, MXI1, IL4, TP53INP1, 
SH3BP2, MDM2, STX2, CSF1R, XPA, FZR1, GNAS, BCL2L1, 
CCNG2, CDKN1A, CDKN1B 
 Cellular 
Development 
 B2M, HIST1H1C, ZFP36, AHSP, MBP, CD55, PDPK1, CD74, 
JAK2, BCL6, LOC643751, IDH1, EP300, TOP1, SLFN1, IGF1, 
UBE2B, OSM, STAT1, HGS, STK17B, IL4, MED7, DNASE2, 
AP3D1, SCD2, MDM2, STX2, AXL, CSF1R, WWP2, TLR2, 
LY6A, BCL2L1, GNAS, CAPNS1, CD9, GRAP2, CDKN1A, 
ADD1, CDKN1B, PRKCB, PRDX2 
 Molecular 
Transport 
 B2M, ASPSCR1, AHSP, HEXA, PDPK1, CD74, SLC2A3, IDH1, 
RFFL, USO1, ANXA1, AP2M1, AP3D1, RAB10, SOAT1, 
CSF1R, NFE2L1, CHIC2, TLR2, UROD, CSF2RB, ARF5, 




 USO1, AP2M1, ASPSCR1, ARF5, AP3D1, USE1, RAB10, 
CD74, SOAT1, CHIC2, RFFL 
 Cellular 
Movement 
 TCIRG1, CD55, LOC643751, AXL, CSF1R, TLR2, ROCK1, 
CSF2RB, IGF1, NDEL1, OSM, PAFAH1B1, IL4 
 Cell 
Morphology 
 ATG12, ULK1, AHSP, PDPK1, HBP1, LOC643751, PSME3, 
ISG15, ROCK1, TLR2, BCL2L1, ST5, CAPNS1, IGF1, STRADB, 
ANXA1, CDKN1A, IRGM, CDKN1B, PAFAH1B1, HGS, 







 The genes downregulated during normal erythroid maturation (Gene susbset 
iii) control cellular processes that are shutdown during late stage erythroid 
maturation – gene expression, RNA post-transcriptional modification, cell 
death, cell cycle and DNA replication and repair (Figure 22 and Table 6). In 
late stage erythroblasts, DNA replication and RNA transcription are largely 
shutdown, followed by which the highly condensed nucleus is then extruded 
out of the cell membrane. Consistent with this, the genes controlling these 
pathways were downregulated in the in vitro cultured erythroblasts (Figure 22 
and Table 6)   The expression pattern of these genes in Myc-GFPhigh cells 
was similar to that of early erythroblasts (D0 WT), and that of Myc-GFPlow 
cells was closer to differentiated late stage erythroblasts (D2 WT). 
 
            
 
Figure 22.  The top significantly enriched gene ontology categories in the genes 
downregulated during normal terminal erythroid maturation but unchanged in 
Myc-GFPhigh cells (Gene subset iii), as identified by Ingenuity pathway analysis 
software. 
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Table 6. Genes downregulated in D2 WT cells but unaffected in Myc-GFPhigh 








 NARG1, YWHAE, NPM3, CD3EAP, TCOF1, POLR1E, 




 QTRT1, NPM1, SRPK1, BOP1, NPM3, WDR55, SFRS13A, 
IMP4, RSRC1 




 NPM1, C14ORF169, HDAC2, AATF, HSF1, ABCA3, SRF, 
RBBP7, RANBP1, HMGN1, TPP2, SKP2, PARP1, PES1, BOP1, 





 MCM6, C14ORF169, HDAC2, HSF1, RBBP7, PSMC3IP, 
RAD54L, HMGN1, POLD1, TPP2, MCM4, SKP2, PARP1, 
MND1, QTRT1, PRMT7, TFAM, XRCC6, HUS1, MSH6, KIF11, 
RTEL1, UNG, MCM7 
 Cell Cycle 
 C14ORF169, HDAC2, COX10, HSF1, RBBP7, PSMC3IP, 
DDX3X, RANBP1, HMGN1, SKP2, PARP1, MYBL2, PPP5C, 
KIF11 
 Cellular 
Compromise  PPID, SMN1, EXT2, HSF1, MEF2C, SMARCC1, UNG, PARP1 
 Post-
Translational 
Modification  HSPA8, PDSS1, PFDN2, HSP90AA1 
 
 The genes that are not significantly induced or repressed during terminal 
erythroid maturation but are significantly perturbed upon ectopic Myc 
expression (Gene subset ii) are enriched for gene ontology categories such as 
cell-to-cell signaling, cellular movement, general cellular maintenance, 
carbohydrate metabolism, cell cycle and molecular transport (Figure 23 and 
Table 7). These are well known molecular and cellular functions regulated by 
Myc and its target genes51. The deregulation of these fundamental cellular 
processes is one of the mechanisms by which Myc disrupts normal cellular 
functions in Myc induced tumors, besides a simple block in differentiation and 
promoting uncontrolled cell division even in the absence of external mitogenic 
signals. 
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Figure 23.  The top significantly enriched gene ontology categories in the genes 
that do not change significantly during normal terminal erythroid maturation 
but are perturbed significantly in Myc-GFPlow cells (Gene subset ii), as 
identified by Ingenuity pathway analysis software. 
 
Table 7. Genes that do not change significantly in D2 WT cells but are perturbed 










 SELL, ADRBK1, ELANE, PRF1, SPHK2, PIK3CG, ATG5, 
PTPN6, PTPRE, TIAM1, MIF, PSMB5, PLEC1, IFNGR1, IRF1, 
F2RL3, PRDX3, GP5, PRTN3, LAT, CLCN7, GP1BB, ELMO1, 
AOC3, ITGA2B, F2RL2, PSMB10, CTNNA1, P2RX1, MFGE8, 
BECN1, OGT, RASSF5, CASP8, MAPKAPK2, CALR, RAB21, 
FCGR2A, VWF, VIM, ALS2, SELPLG, CCL9, CEBPE, PSME1, 
MAPK14, SWAP70, CORO1A, CD44, AP3B1, PIK3CB 
 Cellular 
Movement 
 GBX2, AOC3, RAF1, ITGA2B, SELL, PLCB2, ADRBK1, 
ELANE, PDPK1, TGFBR2, PRF1, ST8SIA4, SPHK2, PIK3CG, 
IRS2, RASSF5, GSK3B, MAPKAPK2, FRS2, CALR, TIMP3, 
PTPN6, TIAM1, RAB21, FCGR2A, PLEC1, IFNGR1, BAX, 
SELPLG, CEBPE, IL16, SWAP70, MAPK14, CYTIP, PRTN3, 




 CTNNA1, ELANE, MFGE8, IKZF1, BECN1, RICTOR, DEF6, 
TGFBR2, PRF1, PIK3CG, IRS2, MAPKAPK2, CASP8, ATG5, 
CALR, FCGR2A, IFNGR1, BAX, IER3, HSPA2, MLST8, IRF1, 
CEBPE, MAPK14, ST3GAL1, LAT, CORO1A, CD44, AP3B1, 
PIK3CB, ELMO1, LGALS1 
 Cellular 
Development 
 PHC2, ELANE, IKZF1, DEF6, TGFBR2, GPC1, PRF1, PIK3CG, 
ATF4, ARID3A, CASP8, HIPK2, TIAM1, IFNGR1, BAX, IER3, 





 F2RL2, MECP2, GM2A, H6PD, PIP4K2B, GCLC, PFKL, TPI1, 
F2RL3, MAPK14, HK2, CHKA, IRS2 
 Cell Cycle  MIF, PHC2, BAX, BECN1, GRB10, GPC1, MAPK14, SPHK2, 
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XPC, ARID3A, RASSF5, POLK, PML, PLAC8 
 Molecular 
Transport 
 F2RL2, FCGR2A, RAB2A, P2RX1, F2RL3, TMED10, GLB1, 




 F2RL2, PDIA3, FCGR2A, GM2A, P2RX1, H6PD, GCLC, GNAZ, 
PFKL, BAX, F2RL3, PRDX3, SPHK2, GLB1, PIK3CG, PAPSS1, 
PAOX, NCOR1, IRS2, SGPP1, SLC19A2, HSD17B4, AIFM1 
 
In summary, continued Myc expression even at a physiological level had 
significant effects on the gene expression patterns observed in late stage 
erythroid cells, suggesting that although overall terminal differentiation was 
normal in terms of hemoglobin levels and expression of major red cell proteins, 
there may be other abnormal changes in these cells besides a block in 
enucleation. Ectopic Myc expression at supraphysiological levels prevented 
the induction of several key erythroid genes, leading to a block in terminal 
erythroid differentiation. 
 
3.17. G1-S checkpoint and erythropoietin signaling pathways are 
dysregulated by Myc overexpression at supraphysiological levels 
In order to better understand the continued proliferation of Myc-GFPhigh cells 
at the expense of terminal differentiation, the genes differentially expressed in 
Myc-GFPhigh cells compared to D2 WT erythroblasts were overlaid onto the 
pathways in the Ingenuity pathways knowledgebase. The significantly (at least 
2-fold) upregulated genes are shown in red and the significantly 
downregulated genes are shown in green. We were particularly interested in 
the G1-S checkpoint regulation pathway since the Myc-GFPhigh cells do not 
arrest in the G1 phase of the cell cycle at the end of 48 hours in culture; and 
the erythropoietin signaling pathway since the Myc-GFPhigh cells showed 




Figure 24.  Myc regulated genes in the G1-S checkpoint regulation. The list of 
genes significantly upregulated or downregulated in Myc-GFPhigh cells relative to 
D2 Wt cells were loaded on to Ingenuity pathways analysis. The cell cycle G1/S 
checkpoint regulation pathway diagram is shown. The upregulated genes are shown 
in red and downregulated genes are shown in green. 
 
The changes in expression of genes that regulate the G1-S transition 
checkpoint in Myc-GFPhigh cells seem to promote proliferation (Figure 24). 
As discussed in detail before, the expression of the cell cycle inhibitor p27 is 
downregulated by ectopic Myc expression at supraphysiological levels. Cyclin 
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E, a critical mediator of G1-S transition121,140, was also upregulated in Myc-
GFPhigh cells. The Cdc25A phosphatase is a well known regulator of the G1-
S checkpoint, and its levels reportedly determine the balance of proliferation 
and checkpoint response141. The Cdc25A knockout mice die on embryonic 
days 5-7, demonstrating that Cdc25A is essential for embryonic 
development142. A naturally occurring point mutation is Cdc25A, which 
increases the Cdc25A activity, has been reported to increase the levels of 
BFU-E cell cycling143. This study suggested that well regulated Cdc25A 
activity is essential for normal erythropoiesis. In Myc-GFPhigh cells, Cdc25A 
levels are upregulated compared to normal late stage erythroblasts (D2 WT). 
This increased expression levels of Cdc25A is consistent with the observed 
increased proliferation demonstrated by the Myc-GFPhigh cells. The nucleolar 
growth regulating protein EBP1144 was also upregulated in Myc-GFPhigh cells. 
The EBP1 knockout mice were about 30% smaller in size than wild-type mice 
and the proliferation rates of day 12.5 embryonic fibroblasts derived from 
EBP1 knockout embryos was lower than that of wild type embryonic 
fibroblasts, indicating that EBP1 plays important roles in regulating cell 
proliferation and organism size145. The findings of these studies suggest that 
upregulation of EBP1 in Myc-GFPhigh cells may play a role in promoting 
proliferation in these cells. 
 
Since Myc-GFPhigh cells were blocked in erythroid differentiation, we 
observed the expression patterns of genes that are a component of the 
erythropoietin signaling pathway using the differentially expressed genes list 
from the microarray data. The transcript levels of the key erythroid 
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transcription factors GATA-1 and EKLF (Erythroid Kruppel-like factor or 
Klf1) did not change significantly in both Myc-GFPlow and Myc-GFPhigh 
cells. Several genes such as protein kinase C delta (Prkcd), Janus Kinase 2 
(Jak2), Protein Kinase B, gamma (Akt3), Bcl-XL, Rac2, cyclin G2 (Ccng2) 
and Hras were perturbed significantly (> 2-fold change relative to control) in 
Myc-GFPhigh cells, and showed modest changes in expression in Myc-
GFPlow cells in the Micro-array data. The expression changes for these genes 





Figure 25. Several genes downstream of the erythropoietin signaling pathway 
are perturbed by ectopic Myc expression.  TER119-negative fetal liver 
erythroblasts were infected with bicistronic retroviruses encoding GFP only as control, 
or both Myc and GFP at 0 hours in culture. At 24 hours post infection, cells were 
sorted based on GFP intensity into low (Myc-GFPlow) and high (Myc-GFPhigh) 
intensity populations, and then cultured for another 24 hours to allow for 
differentiation. The control cells (Control), Myc-GFPlow and Myc-GFPhigh cells 
were harvested from culture at 48 hours post-infection, and qRT-PCR analysis was 
performed to measure relative mRNA levels of the indicated genes. Error bars 
represent standard deviation (n=3). Two-tailed t-test results are indicated by (**) 




Most of these genes, namely Prkcd, Jak2, Akt3, Bcl-XL and cyclin G2 were 
significantly downregulated in Myc-GFPhigh cells, consistent with the 
observed differentiation block in these cells. The downregulation of these 
genes may contribute to deregulation of the erythropoietin signaling pathway 
that is crucial for terminal erythroid maturation of CFU-Es. These genes are 
either modestly reduced in expression or remain relatively unchanged in Myc-
GFPlow cells, suggesting that the erythropoietin signaling pathway may not be 
perturbed significantly enough in these cells to disrupt terminal erythroid 
differentiation, as evidenced by the normal upregulation of TER119 and 
hemoglobin expression in Myc-GFPlow cells (Figures 2 and 3).  
 
The Jak2 tyrosine kinase is activated upon erythropoietin binding to the 
erythropoietin receptor146, and in turn activated Jak2 phosporylates several 
tyrosine residues in the cytoplasmic domain of the erythropoietin receptor 
which function as docking sites for Src-homology domain (SH2 domain) 
containing proteins. Jak2 deficient mice die on embryonic day 12.5 due to 
failure of definitive erythropoiesis, and the fetal livers demonstrate complete 
lack of BFU-Es and CFU-Es though multilineage hematopoietic progenitors 
were present147,148. Hence deregulated expression of Jak2 by ectopic Myc 
expression (Figure 25) may contribute to the defects in terminal differentiation 
in Myc-GFPhigh cells.  
 
Protein Kinase C (PKC) activity has been reported to be critical for normal 
CFU-E colony formation, and chemical inhibitors of PKC inhibit in vitro 
colony formation by CFU-Es from normal and Friend virus-infected mice149. 
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Another study using K562 cells are model of erythroid differentiation showed 
that bisindolylmaleimide (GF109203X), an inhibitor of protein kinase C, 
inhibited erythroid differentiation of K562 cells by decrease in expression of 
several erythroid transcripts and reduction in the number of hemoglobinized 
cells150. The conclusions from these studies suggest that downregulation of 
Prkcd in Myc-GFPhigh cells (Figure 25) may contribute to the block in 
terminal erythroid differentiation in these cells. 
 
The role of AKT in terminal erythropoiesis was worked out by earlier studies 
in our lab. The PI3K/AKT pathway was shown to play a role in 
phosphorylation and activation of GATA-1 by erythropoietin signaling151, 
providing the first direct link between erythropoietin signaling and activation 
of GATA-1, both of which are required for normal terminal erythropoiesis.  
Overexpression of a constitutively active mutant of AKT was able to rescue 
the erythroid cell maturation defect observed in Jak2-null fetal liver 
erythroblasts152, showing that AKT complements the EPOR/JAK2 signaling 
pathway in regulating terminal erythroid maturation. The transcript levels of 
akt3, one of the 3 isoforms of AKT, was relatively unchanged in Myc-GFPlow 
cells, but was significantly reduced in Myc-GFPhigh cells (Figure 25) 
suggesting a possible mechanism for the block in differentiation demonstrated 
by these cells. 
 
The anti-apoptotic gene Bcl-XL is induced by erythropoietin signaling via 
Stat5153,154, and provides protection against apoptotic cell death during the 
process of terminal erythroid maturation of CFU-Es. Ectopic expression of 
Bcl-XL was able to support erythropoietin-independent differentiation of 
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primary erythroblasts155, suggesting that induction of Bcl-XL is one of the 
major functions of erythropoietin signaling in regulating terminal erythroid 
maturation. The level of Bcl-XL mRNA was slightly decreased in Myc-
GFPlow cells, but significantly reduced in Myc-GFPhigh cells (Figure 25). 
Although this may not directly contribute to the differentiation block seen in 
the Myc-GFPhigh cells, it explains the high levels of apoptosis demonstrated 
by Myc-GFPhigh cells, but not by Myc-GFPlow cells which still express 
significantly high levels of the Bcl-XL transcript and hence are protected from 
Myc-induced apoptosis. 
 
Rac2 is a member of the Rac subfamily of the Rho family of small GTPases 
whose expression is limited to the hematopoietic lineage. Rac2 expression was 
downregulated in dose dependent manner by ectopic Myc expression. 
Deregulation of Rac activity blocks enucleation by disruption of the formation 
of the contractile actin ring (CAR) required for the ejection of the condensed 
nucleus from the incipient reticulocyte33. Rac2 expression is upregulated 
during late stages of erythroid maturation coinciding with the beginning of 
enucleation. GATA-1 has been suggested to play a role in the induction of 
Rac2 during terminal erythroid maturation156. The upregulation of Rac2 
expression is significantly inhibited in a dose-dependent manner by ectopic 
Myc expression (Figure 25), suggesting that disruption of Rac2 expression 
may contribute to the enucleation block besides the inhibition of nuclear 
condensation and histone deacetylation by Myc. We performed chromatin 
immunoprecipitation using Myc antibodies in cultured erythroblasts, and used 
primers designed for Rac2 promoter regions to test enrichment of Myc binding 
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in these sites by ChIP-qRT-PCR. We did not observe significant enrichment of 
the Rac2 promoter sequences in the ChIP DNA (Data not shown), suggesting 
that the downregulation of Rac2 by Myc is most likely not due to the 
repression of Rac2 expression by direct binding of Myc to the Rac2 promoter. 
 
The inhibitory cyclin G2 (Ccng2) is downregulated upon erythropoietin 
stimulation of murine primary bone marrow erythroblasts157. Post-mitotic cells 
show high levels of cyclin G2 expression, and unlike conventional cyclins, it 
blocks cell cycle entry158. This suggests that cyclin G2 might play a role in the 
exit from cell cycle during terminal erythroid maturation. Consistent with its 
role as a negative regulator of cell cycle, Myc-GFPlow cells that exit the cell 
cycle normally express normal levels of cyclin G2, wheras Myc-GFPhigh cells 
that continue to proliferate show dramatically reduced expression of cyclin G2 
mRNA (Figure 25).  
 
H-ras expression was upregulated in a dose-dependent manner upon ectopic 
Myc expression (Figure 25). Studies in a cell line model of erythroid 
differentiation derived from Friend virus-induced murine erythroleukemia 
demonstrated that downregulation of the Ras/ERK signaling pathway may be 
essential for terminal erythroid differentiation159. Dominant negative mutant of 
H-ras promoted erythroid differentiation even in the absence of erythropoietin, 
while a constitutive active mutant of H-ras blocked the erythropoietin-induced 
differentiation in these cells. The role of Ras signaling in terminal erythroid 
differentiation was investigated as one of the earliest applications of the in 
vitro culture system using purified primary mouse fetal erythroblasts10. 
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Overexpression of oncogenic H-ras, but not dominant negative H-ras, was able 
to block the differentiation of in vitro cultured fetal liver erythroid progenitors. 
Wild type H-ras showed a mild blocking effect on terminal erythroid 
differentiation, compared to the strong block in differentiation exerted by 
oncogenic H-ras10. The cells overexpressing oncogenic H-ras continued to 
proliferate in culture in the absence of erythropoietin for about a week. This is 
similar to the phenotype displayed by the Myc-GFPhigh cells, that continue to 
proliferate for over 8 weeks in an early erythroblast morphology, suggesting 
that a common mechanism may regulate the differentiation block in cells 
overexpressing Myc or oncogenic H-ras. Myc-GFPlow cells upregulate H-ras 
expression by about 1.5 fold, and the normal expression of other key cell cycle 
genes such as p27 and cyclin G2 may prevent continued proliferation of these 
cells. In Myc-GFPhigh cells, the increased H-ras levels may find a suitable 
transcriptional environment to exert its differentiation blocking effect. The 
overexpression of two different protooncogenes Ras and Myc give similar 
phenotypic outcomes, namely proliferation at the expense of differentiation, 
suggesting that the proliferation machinery in erythroid cells may not be 
entirely independent of the differentiation machinery. Further studies are 
required to elucidate the precise molecular mechanism by which Myc and H-
ras regulate differentiation and proliferation during terminal erythroid 
maturation. 
 
Taken together, gene expression analysis demonstrated that Myc-GFPlow 
cells are similar to differentiated late stage erythroblasts (D2 WT) and Myc-
GFPhigh cells resembled the early erythroblasts (D0 WT).  Several key 
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erythroid transcripts were blocked in Myc-GFPhigh cells confirming a block 
in erythroid differentiation. Some of these erythroid transcripts were also 
perturbed in Myc-GFPlow cells, but no major abnormality was detectable 
except for a block in enucleation. There may be other defects in the Myc-
GFPlow erythroid cells that are not apparent in our assays for evaluating 
erythroid differentiation. The G1-S checkpoint genes and the erythropoietin 
signaling pathway genes were significantly perturbed in Myc-GFPhigh cells, 
explaining the continued proliferation at the expense of terminal 
differentiation demonstrated by these cells. 
 
3.18. Summary of Results 
We demonstrate that ectopic Myc expression has a dose-dependent effect on 
terminal erythroid differentiation of purified mouse fetal liver erythroblasts 
cultured in vitro. Ectopic Myc expression at physiological levels specifically 
blocks enucleation without affecting terminal erythroid maturation, while 
overexpression of Myc at levels above the physiological range promotes 
proliferation of the erythroblasts at the expense of differentiation as well as 
evoking an apoptotic response. We investigated the specific histone 
acetylation changes that are induced by ectopic Myc expression to show that 
ectopic Myc blocks histone deacetylation observed during late stages of 
erythroid maturation. We identified the histone acetyltransferase (HAT) Gcn5 
to be upregulated by Myc. Ectopic Gcn5 expression inhibited the decrease in 
histone acetylation and nuclear condensation, further supporting the theory 
that histone deacetylation is necessary for erythroid nuclear condensation and 
enucleation. We confirmed by chromatin immunoprecipitation studies that 
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Myc binds to the Gcn5 promoter in erythroid cells. Our study indicates that 
Myc levels play a critical role in regulating the balance between proliferation 
and differentiation in the erythroid lineage. Our data uncovers an important 
role for Myc in erythroid nuclear condensation and enucleation, and provides 




CHAPTER 4 – DISCUSSION 
4.1. Downregulation of Myc is essential for terminal erythroid maturation 
 
The present study uncovers the significance of changes in Myc expression in 
controlling mammalian terminal erythroid differentiation. Myc is normally 
downregulated beginning at the CFU-E stage. We demonstrate that 
overexpression of Myc at levels above that of these early erythroblasts 
promotes proliferation at the expense of differentiation, and is accompanied by 
induction of the apoptotic machinery. In contrast, continued Myc expression at 
low levels blocks enucleation without affecting terminal erythroid 
differentiation and proliferation. The block in enucleation by Myc is 
accompanied by a significant block in nuclear condensation in late stage 
erythroblasts. We further show that ectopic Myc prevents the decrease in 
histone acetylation during the final stages of erythroid maturation, suggesting 
that the block in nuclear condensation and enucleation may be a direct result 
of the effect of Myc on global histone acetylation states. Our results support a 
model whereby down-regulation of Myc from the high levels seen in early 
erythroblasts is essential for the progression of normal terminal erythroid 
differentiation and enucleation.  
 
Upon erythropoietin induction of terminal differentiation, the mouse 
erythroblasts undergo about 4-5 terminal cell divisions in 48 hours followed 
by a G1-phase cell cycle arrest. The mechanism of regulation of these rapid 
terminal cell divisions followed by a G1 arrest is not well understood. 
Upregulation of p27 during late stage erythroid differentiation has been 
implicated in regulating the withdrawal of erythroid cells from cell cycle11.  
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Figure 26. Model for role of Myc in terminal erythroid maturation. Myc 
expression is progressively downregulated starting from the early erythroblast 
stage (0h in culture) through partially hemoglobinized erythroblasts (24h in 
culture) to the completely differentiated and enucleated reticulocytes (48 h in 
culture). The downregulation of Myc is essential not only for the proliferation 
arrest, but also the progression of normal differentiation, nuclear condensation 
and enucleation of erythroid cells. 
 
 
However, we demonstrated using p27 knockout erythroblasts that terminal 
erythroid differentiation is unaffected by the absence of p27, suggesting that 
p27 alone is not sufficient to regulate the late stage G1 arrest in erythroid cells.  
We provide evidence suggesting that Myc plays a critical role in controlling 
the number of terminal cell divisions and the withdrawal from the cell cycle. 
shRNA-mediated depletion of Myc in cultured erythroblasts significantly 
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inhibited terminal cell proliferation without affecting terminal differentiation, 
indicating that a precisely regulated decrease in Myc levels during late stage 
erythroid maturation may control the exact number of terminal cell divisions 
before the cell cycle arrest. Myc levels were dramatically reduced during late 
stages of erythroid maturation, coinciding with the arrest in G1-phase of the 
cell cycle. Ectopic Myc expression maintained at a level similar to that of 
early erythroblasts promotes their proliferation in culture for much longer 
times in an undifferentiated state. This suggests that downregulation of Myc 
levels below a critical threshold might be necessary for commitment towards 
both terminal erythroid maturation and the withdrawal from the cell cycle. 
 
Several studies have attempted to elucidate the role of Myc in terminal 
erythroid maturation. Rylski et al. used the G1E erythroid cell line, a GATA-1 
null immortalized erythroblast cell line that undergoes terminal erythroid 
differentiation when the GATA-1 function is restored, as their model system 
for studying terminal erythropoiesis. They reported that ectopic Myc 
expression prevented exit from the cell cycle but did not block terminal 
erythroid maturation induced by GATA-1119. This study provided evidence for 
GATA-1 binding to the Myc promoter, and proposed direct repression of Myc 
expression by GATA-1 during terminal erythroid maturation as a mechanism 
to regulate the exit from cell cycle. GATA-1 repression of Myc indeed 
provides a compelling mechanism for the tight and simultaneous regulation of 
the differentiation and proliferation programme during terminal erythroid 
maturation. Rylski et al. used MycER induction by estradiol to induce ectopic 
Myc activity in G1E cells, and the level of expression reported was stated to 
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be slightly above the levels of endogeneous Myc expression in normal G1E 
cells without MycER. They further state that “Myc-ER cells were slightly 
larger and exhibited a broader TER119 profile, indicating that enforced Myc 
affected the maturation program to a minor extent”. From the conclusions 
from our current study, we interpret that this larger cell size and broader 
TER119 profile observed by Rylski et al. to represent a partial block in 
differentiation due to the MycER protein in some cells being expressed at 
levels higher than the physiological range. These cells continue to enter the S-
phase of the cell cycle in culture, alongside the cells expressing MycER at a 
phsyiological level which differentiate normally and exit the cell cyle, giving 
rise to a mixed population where maturation seems to proceed simulataneously 
with proliferation. Our model where Myc expression has a dose-dependant 
effect on terminal erythroid maturation, explains the observations made by 
Rylski et al. very well.  
 
Another recent report by Acosta et al. that addressed the role of Myc in 
erythroid maturation using the p27-induced erythroid differentiation in K562 
human erythroleukemia cells as a model system concluded that Myc inhibited 
erythroid differentiation by repressing key erythroid genes without preventing 
the exit from the cell cycle120. The ectopic Myc was provided by transfection 
of MycER constructs and activation by 4-OHT. Similar to our results using 
MycER overexpression in primary mouse fetal liver erythroblasts, activation 
of MycER led to block in erythroid differentiation. This study concluded that 
the block in differentiation was due the repression of several key erythroid 
transcripts, including GATA1, by Myc. We demonstrate in our study using 
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primary erythroid cells that Myc expression indeed blocks several key 
erythroid genes involved in the erythropoietin signaling pathway, although the 
expression of GATA-1 was not significantly affected by Myc expression. 
Acosta et al. also noted that Myc expression was unable to induce gene 
expression changes that can reverse the cell cycle arrest. In our study, Myc 
overexpression at supraphysiological levels in primary mouse erythroblasts 
significantly perturbs genes involved in the G1/S transition (Figure 24), 
consistent with the continued cycling of the Myc-GFPhigh cells. Observations 
made by a previous study129 that reported generation of actively dividing 
immature erythroblast cell lines by retroviral overexpression of Myc in 
unfractionated mouse fetal liver cells are in agreement with our finding that 
Myc overexpression enhanced the self-renewal ability of primary erythroblasts 
at the expense of differentiation. In summary, the contrasting observations 
made by Rylski et al. and Acosta et al. may be due to the inherent differences 
in the different immortalized cell line model systems of erythroid 
differentiation used in these studies. We propose from our observations made 
in primary erythroblasts that the levels of Myc expression play an important 
role in regulating differentiation, proliferation and survival during terminal 
erythroid maturation. 
 
4.2. Myc regulates global histone acetylation and erythroid enucleation 
Due to its well-established roles in driving cell proliferation, repression of 
Myc during late stage erythroid maturation has been suggested to be involved 
mainly in the withdrawal from cell cycle. Our data demonstrates that normal 
downregulation of Myc in late stage erythroid cells is also essential for 
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chromatin condensation and enucleation, revealing a novel role for Myc in 
mammalian erythropoiesis. We show that downregulation of Myc during 
terminal erythroid maturation is accompanied by a global decrease in histone 
acetylation at several N-terminal lysine residues in histones H3 and H4, and 
ectopic Myc expression at low levels that did not induce cell cycle re-entry 
was sufficient to block the global histone deacetylation and inhibit chromatin 
condensation and enucleation. These findings strongly support the emerging 
notion that Myc regulates global chromatin structure by influencing genome-
wide histone modifications135-137.  
 
One of earliest conclusive studies on Myc’s role in regulating global 
chromatin structure was done by Knoepfler et al., who reported that Myc 
proteins are required for general maintenance of active chromatin136,137.  They 
used a conditional knockout of N-Myc in mouse neuronal progenitors, and 
showed that disruption of N-Myc led to nuclear condensation accompanied by 
large scale changes in global histone acetylation. Knoepfler et al. further 
showed that the Myc direct target HAT Gcn5 contributed in part to the 
regulation of global acetylation states and chromatin structure by Myc. This 
showed that Myc’s influence on global chromatin structure is not just due to 
its well known widespread binding, but also due to its ability to increase 
histone acetylation through histone acetyltransferases such as Gcn5. Myc has 
been shown to induce acetylation of histone H4 and this has been suggested to 
contribute to transcriptional activation160. Guccione et al. have shown that 
Myc binding site recognition in the human genome is dependent on the 
chromatin context135.  In a subsequent study using a human B-cell line with a 
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regulatable Myc trangene, Guccione et al. demonstrated that Myc binding 
promoted histone acetylation at H3K9, H3K14, H3K18, H4K5, H4K8 H4K12, 
H4K91 and H2AK5 at its target promoters161. They report that a majority of 
target promoters tested showed co-induction of multiple histone marks in 
various combinations. In our present study, we demonstrate that Myc induces 
increase in histone acetylation at a global level in several of the lysines shown 
to be acetylated in Myc target promoters by Guccione et al.161. These studies 
conclusively showed that Myc influences global chromatin structure and 
transcriptional activity by influencing histone modifications. Our results 
further strengthen the notion of Myc regulation of global chromatin structure, 
and indicate that this function of Myc plays a critical role in regulating 
erythroid enucleation which is a hallmark of mammalian red blood cell 
development. 
 
In our study, ectopic Myc expression inhibited late stage erythroid nuclear 
condensation and enucleation, and rescued the decrease in global histone 
acetylation during late stages of erythroid maturation. Our results strongly 
support the model proposed by Popova et al., where global histone acetylation 
changes regulate nuclear condensation and enucleation in erythroid cells127. 
Epigenetic regulation of chromatin condensation can explain the selective 
transcription of certain critical genes such as Bcl-XL7 during late stage 
erythroid maturation when DNA replication and RNA transcription in the 
condensed nucleus are largely shutdown. It also allows for a rapid 
condensation and general inactivation of the erythroid nucleus in a manner 
similar to apoptotic nuclear condensation, while also leaving the general 
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nuclear architecture and chromosomal DNA intact32. While our results are 
strongly consistent with epigenetic regulation of erythroid chromatin 
condensation127, they do not exclude the possibility that other genes activated 
by repression of Myc during late stage erythroid maturation may also act as 
important regulators of erythroid enucleation. 
 
4.3. Histone acetyltransferases in terminal erythroid maturation: the role 
of Gcn5 
Acetylation of specific lysine residues in histones H3 and H4 tails has 
generally been associated with an open and transcriptionally active chromatin 
state, whereas deacetylation at these residues is associated with gene 
repression162-164. The histone acetylation states are governed by histone 
acetyltransferases (HATs) and histone deacetylases (HDACs), and the balance 
between the activity of these enzymes play fundamental roles in regulation of 
transcription. The balance in these enzyme activities is essential for normal 
cellular processes including proliferation and differentiation (reviewed in 
detail by Lehmann et al.165). Knockout mouse models have provided important 
clues about the roles of these histone modifying enzymes in development. 
Mice deficient for Gcn5 die on embryonic day 8.5 due to failure of mesoderm 
formation, while the related gene PCAF which shares similar sequence and 
enzyme activities was dispensable in mice166. Embryos double null for both 
Gcn5 and PCAF showed more severe defects indicating a significant overlap 
in the fuction of these HATs during embryogenesis166. Mouse homozygous for 
point mutations in the catalytic domain of the Gcn5 HAT survived 
significantly longer than the Gcn5 knockout mice but showed severe neural 
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tube closure defects and exencephaly167, indicating that Gcn5 has important 
HAT-independent functions in embryonic development. CBP and p300 are 
closely related HATs and transcriptional coactivators that participate in 
multiple signaling-mediated transcription events168. Loss of CBP or p300 leads 
to midgestation lethality in mice between embryonic day 9 and 11.5 due to 
severe developmental defects169. CBP/p300 double heterozygotes are also 
embryonic lethal, and p300+/- mice showed considerable embryonic lethality 
but most survived. But CBP+/- mice showed features of Rubinstein Taybi 
syndrome (RTS), a genetic disease characterised by severe developmental 
defects and mental retardation169,170. These observations suggest that CBP and 
p300 have both overlapping and unique functions in development, and the 
dosage of these genes are critical for their normal cellular functions. Recent 
studies report that 25% of the mice heterozygous for both Gcn5 and p300 die 
in utero, indicating that the dosage of these gene products are critical for 
development171. Just like HATs, HDACs have specialised and tissue specific 
functions revealed by knockout mice studies (reviewed by Haberland et al.172). 
For example, HDAC1 knockout mice173 die before E10.5 due to general 
growth retardation and HDAC3 knockouts174 die before E9.5 due to defective 
gastrulation. HDAC4 is essential for normal chondrogenesis175. Mice lacking 
both HDAC5 and HDAC9 show a propensity for cardiac developmental 
defects, but the individual knockouts are normal suggesting that these HDACs 
have redundant roles in cardiac development176. These studies show that 
HATs and HDACs have higly specific functions in development and disease. 




We identified the HAT Gcn5 to be induced by Myc in erythroid cells, and 
demonstrated its role in regulation of global histone deacetylation and nuclear 
condensation in late stage erythroblasts. Gcn5 expression was downregulated 
during late stages of erythroid maturation suggesting that it may play a role in 
the loss of global histone acetylation and nuclear condensation. 
Overexpression of Gcn5 led to a partial but significant block in enucleation, 
and we further demonstrated that Gcn5 overexpressing cells were also 
significantly inhibited in nuclear condensation. Gcn5 was able to rescue the 
global histone deacetylation in late stage erythroid cells, suggesting that the 
Myc-Gcn5 pathway was a critical regulator of nuclear condensation and 
enucleation in erythroid cells. This function of Gcn5 is consistent with 
previous studies in yeast showing that Gcn5 was required either directly or 
indirectly for the acetylation of several sites in histones H3 and H4177. Gcn5 is 
a part of at least two large multiprotein complexes that are capable of 
regulating global histone acetylation178.   Gcn5 had been shown to be a direct 
Myc target in human fibroblasts137. We confirmed using chromatin 
immunoprecipitation studies that the Gcn5 promoter is bound by Myc in 
erythroid cells. The inhibition of enucleation by Gcn5 expression was not as 
complete as that of Myc, suggesting that there might be additional 
mechanisms other than induction of Gcn5, by which Myc can regulate 
erythroid nuclear condensation and enucleation.  
 
Several HATs such as Elp3, Hat1, Tip60 and Gcn5 were downregulated 
during the late stages of terminal erythoid maturation. The cumulative effect 
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of downregulation of these multiple HATs may contribute to shifting the 
balance between the HAT activity and HDAC activity in the cell in favour of 
HDACs, leading to the observed decrease in global histone acetylation during 
late stage erythroblast maturation. Overexpression of Elp3, Hat1 or Tip60 did 
not block enucleation significantly suggesting that the HATs are not 
individually sufficient to regulate enucleation. PCAF levels did not decrease 
significantly during the course of erythroid maturation, and its ectopic 
expression had no apparent effect on enucleation or terminal differentiation of 
cultured erythroblasts. The size limitations in a retroviral gene delivery system 
prevented us from testing the roles of CBP and p300 HATs in terminal 
erythroid differentiation, since the coding sequence for these genes were 
greater than the 5.5 Kb size limit on inserts that can be efficiently packaged 
into a retrovirus particle. Myc expression at physiological levels did not 
significantly perturb the expression of any of the HDACs tested, although 
changes in expression of HDACs may play significant roles in late stage 
erythroid maturation and enucleation, especially in reducing the global histone 
acetylation during late stage erythroid maturation when the HAT activities are 
downregulated. Our study provides the first conclusive evidence for the role of 
any histone acetyltransferase in regulating mammalian terminal erythroid 
maturation and enucleation.  
 
4.4. Dose of Myc expression is critical in determining its biological 
outcome 
It is generally accepted that ectopic Myc expression promotes proliferation 
and blocks terminal differentiation, which are essential outcomes leading to 
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tumor formation179. Myc also induces apoptosis through the Arf-Mdm2-p53 
tumor suppressor pathway87,90, and additional mutations that overcome the 
induction of apoptosis by Myc lead to tumorigenesis.  We demonstrate here 
that the dosage of Myc is critical in determining the phenotypic outcome of 
ectopic Myc expression on differentiation, proliferation and survival of 
erythroid cells. Continued Myc expression at physiological levels did not elicit 
an apoptotic response in cultured erythroid cells, and broadly allowed for 
terminal maturation with mainly nuclear condensation and enucleation being 
affected. High levels of ectopic Myc promoted proliferation and effectively 
blocked induction of erythroid important genes required for differentiation, 
and also induced significant levels of apoptosis. This supports the theory that 
the apoptotic response is a safeguard against the abnormal proliferation 
mediated by oncogene activation as in the case of high level ectopic Myc 
overexpression, and that low levels of ectopic Myc that do not induce cell 
cycle re-entry do not evoke the apoptotic response either.  
 
An elegant study using an in vivo model of Myc-induced tumorigenesis 
previously showed that activation of the apoptotic pathways required high 
level Myc overexpression, and low level deregulated Myc was potentially 
oncogenic in several but not all tissue types by avoiding the engagement of 
tumor suppression pathways180. In our study using primary erythroid cells 
cultured in vitro, low-dose Myc expression did not induce cell cycle re-entry 
or a complete block in differentiation. Hence expression levels of Myc protein, 
together with other factors such as cell type116, developmental stage and 
context181, controls the phenotypic outcome of ectopic or deregulated Myc 
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expression. A detailed understanding of the functioning of all these factors in 
combination would lead to better therapeutic intervention in cancers that 















CHAPTER 5 – IMPLICATIONS AND FUTURE WORK 
This work is a detailed and systematic analysis of the role of Myc in 
mammalian terminal erythroid maturation. We used an in vitro primary 
erythroid cell culture system to demonstrate that downregulation of Myc is 
essential for normal terminal erythroid maturation and enucleation. We 
provide the first evidence for the role of Myc in regulating erythroid 
enucleation, a hallmark process in mammalian erythropoiesis. We provide 
evidence for the role of histone acetylation in regulating erythroid nuclear 
condensation, and identifed the important role of histone acetyltransferase 
Gcn5 in this regulation. We elucidated that the biological effects of ectopic 
Myc depends on the dose of Myc expression, and characterized the dose-
dependent effect of Myc expression on primary erythroblast differentiation 
using microarray analysis. 
 
This study is the first detailed analysis of the dose-dependent effect of ectopic 
Myc expression on any differentiation pathway. We propose that dose of Myc 
expression, besides other factors like cell type and developmental stage, 
should be taken into account while designing therapeutic strategies for 
treatment of cancers involving deregulated Myc expression. More than 50% of 
human cancers including leukemias involve deregulated Myc expression. 
Blockage of differentiation and promotion of proliferation are two aspects of 
oncogenesis by Myc. We show that Myc blocks terminal erythroid 
differentiation by inhibiting the expression of genes involved in the 
erythropoietin signaling pathway, and promotes expression of genes that 
regulate cell cycle progression. Myc regulation of enucleation also explains 
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the presence of large numbers of nucleated red blood cells in the peripheral 
blood of leukemia patients. Even in cases where the trigger for 
leukemogenesis is not Myc, the proliferation of leukemic cells involves Myc 
activation which in turn may block enucleation. The only other oncogenic 
transcription factor for which a dose-dependent effect has been reported is 
Ras182. Interestingly, we observed that H-ras expression increased in a dose-
dependent manner upon ectopic Myc expression in primary erythroblasts. 
These results argue for careful analysis and identification of dose-dependent 
effects of other oncogenes, and more generally transcription factors, on their 
biological outcomes.  
 
We have established a cellular model of ectopic Myc expression at different 
doses that can be used to investigate the differences between physiological and 
pathophysiological functions of Myc with specific reference to it target genes 
and gene networks51,56. Specifically, this system can be used to investigate 
whether the pathological effects of Myc overexpression is due to quantitative 
alterations of physiological Myc targets or its binding and activation of non-
physiological targets or due to both. We have shown using microarrays that 
Myc overexpression at supraphysiological levels perturbs a large number of 
genes besides those affected by physiological levels of ectopic Myc. ChIP-
sequencing studies can elucidate whether these additional genes activated by 
high level Myc overexpression contain promiscuous Myc binding sites 
different from the physiological Myc binding sites/motifs. The properties of 
any such promiscuous Myc binding sites will be very useful in understanding 
how the Myc target gene network is altered in cancers51,56.  
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Our studies also strongly support the emerging notion that Myc regulates 
global chromatin structure by regulating genome-wide epigenetic changes. We 
show that ectopic Myc prevents late stage erythroid nuclear condensation and 
enucleation, providing direct functional evidence that Myc influences global 
chromatin structure. It is interesting to note that Myc plays a critical role in 
improving the efficiency of reprogramming of somatic cells into an embryonic 
stem cell-like state known as induced pluripotent cells (iPS cells)183 . Myc 
may provide a more “open” chromatin context for the other reprogramming 
factors like Oct4, Sox2 and Klf4 to access and bind to their genomic targets to 
kick-start the pluripotency circuitry. A recent report by Yamanaka and 
colleagues demonstrates that the promotion of iPS generation by Myc is 
independent of its transformation property184. This suggests that other 
functions of Myc such as supression of differentiation-associated genes and 
the regulation of global histone modifications may play critical roles in 
enhancing iPS reprogramming. Small molecule inhibitors of HDAC activity 
have been shown to improve iPS reprogramming efficiency by over 100 fold, 
and enable efficient reprogramming without introduction of Myc185. This 
highlights the role of histone acetylation in regulating the reprogramming 
process, and strongly argues for the role of Myc-induced histone acetylation 
changes in improving reprogramming efficiency. Future work in our lab aims 
to screen various HATs for their ability to enhance reprogramming, since 
ectopic expression of HATs is functionally similar to the use of HDAC 
inhibitors that have been shown to enhance reprogramming. These studies will 
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